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ABSTRACT
Since the early 1950s, biopsychiatric conceptualizations have dominated
empirical, theoretical and therapeutic efforts to understand the treatment of
schizophrenia. The contemporary preeminence of biopsychiatric conceptualizations of
schizophrenia have overshadowed other perspectives that might contribute fruitfully to
our capacity to understand and aid individuals suffering with this devastating emotional
disorder. The origin of modern biopsychiatric conceptualizations is deconstructed by
illuminating the non-epistemic underpinnings of Emil Kraeplin’s dementia praecox
concept, which is the forerunner of the modern schizophrenia construct. Two widely held
assumptions of the biomedical model, namely: 1) that schizophrenia is a degenerative,
organic brain disease; and 2) that neuroleptic medications are the most effective and
safest treatment of schizophrenia are empirically reviewed. Psychodynamic theory and
therapy alternatives are also reviewed empirically and theoretically. The comparative
effectiveness of Psychodynamic Psychotherapy-only (n = 9) and Medication-only (n =
12) was investigated using an experimental design (Karon & VandenBos, 1981). All
patients were administered the Thematic Apperception Test (TAT) at pre- and posttreatment (20 months). Westen’s (1995; Hilsenroth, Stein, & Pinsker, 2004) Social
Cognition and Object Relations Scale (SCORS) was used to rate the pre- and posttreatment TAT narratives in order to assess changes in the cognitive and affective aspects
of patients’ object relations throughout treatment. Jacobson and Truax’ (1991) Clinical
Significance methodology was used to detect clinically significant change for each
individual patient. Results show the SCORS is a reliable and valid instrument for use
with a schizophrenia sample. Treatment outcome results suggest that patients receiving
v

psychodynamic psychotherapy exhibit clinically significant change in a variety of object
relations domains when assessed at the group and individual levels. Comparative
analyses indicated that Psychodynamic Psychotherapy-only patients outperformed
Medication-only patients in regard to changes in a variety of object relations domains.
Medication-only patients did not outperform Psychodynamic Psychotherapy-only
patients in any domain of object relations. Significantly more Medication-only patients
exhibited clinical regression compared to patients receiving psychodynamic
psychotherapy. (Dr. Leonard Handler served as the chairperson of this dissertation
committee.)

vi

TABLE OF CONTENTS
I. INTRODUCTION ........................................................................................................... 1
Section I: Emil Kraeplin, Degeneration Theory, and Philosophical Realism............... 13
Philosophical Realism and Kraeplin’s Dementia Praecox Construct ....................... 17
Section II: The Empirical Validity of the Degenerative Disease Construct ................. 19
Duration of Untreated Schizophrenia: Psychotoxicity and Clinical Outcome ......... 20
Hope or Dread: Longitudinal Studies of Schizophrenia ........................................... 24
Section III: The Effectiveness and Safety of Neuroleptic Medications........................ 32
Effectiveness of the Typical Neuroleptics ................................................................ 32
Effectiveness Research Including Typical and Atypical Neuroleptics..................... 40
Atypical Neuroleptics versus Typical Neuroleptics ................................................. 42
How a Psychiatric Drug Comes to the Marketplace................................................. 43
The RCT: A Scientifically and Clinically Flawed Approach ................................... 45
CATIE: The Largest Naturalistic Study of Neuroleptics to Date ............................. 56
Side-Effects of Neuroleptic Medications.................................................................. 58
Section IV: The Effectiveness of Psychodynamic Psychotherapy of Schizophrenia ... 65
Research Investigating the Psychodynamic Psychotherapy of Schizophrenia ......... 69
II. METHODS................................................................................................................... 75
Section V: Pre- to Post-Treatment Change in the Object Relations of Schizophrenic
Patients.......................................................................................................................... 75
Clinical Participants .................................................................................................. 76
Therapists.................................................................................................................. 80
Explanation of Psychotherapeutic Treatment ........................................................... 81
Measure..................................................................................................................... 82
Explanation of Analyses ........................................................................................... 86
III. RESULTS ................................................................................................................... 93
Convergent and Divergent Validity .......................................................................... 93
Within-Group Analyses of Change........................................................................... 94
Traditional Analyses of Between-Groups Change Using ‘Difference Scores’ ........ 95
‘Recovered’ and/or ‘Positive Response’ to Treatment ............................................. 95
Group Differences for RCI Scores.......................................................................... 101
IV. CONCLUSION......................................................................................................... 103
LIST OF REFERENCES................................................................................................ 116
APPENDIX A................................................................................................................. 144
VITA ............................................................................................................................... 161

vii

LIST OF TABLES
Table

Page

1. Most Commonly Prescribed Neuroleptic Medications for the
Treatment of Schizophrenia……………………………………145
2. Example of Non-Equivalent Dosing…………………………….146
3. Interrater Reliability of the SCORS Variables…………………..147
4. SCORS Means of Outpatients Experiencing Mild to Moderate
Distress as Reported in Peters et al. (2006)………………….....148
5. Convergent and Divergent Validity of the SCORS with a
Schizophrenic Sample………………………………………….149
6. Means, Standard Deviations, and Paired-Samples T Tests for
Psychotherapy Group…………………………………………...150
7. Means, Standard Deviations, and Paired-Samples T Tests for
Medication Group………….…………………………………...151
8. Traditional Analyses of Between-Groups Change Using
‘Difference Scores’……………………………………………..152
9. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’,
‘Positive Response’, and Peters et al. (2006) for SCORS
Complexity of Relationships (COM)………………………….153
10. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’,
‘Positive Response’, and Peters et al. (2006) for SCORS
Affect Tone of Representations (AFF)…….………….………...154
11. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’,
‘Positive Response’, and Peters et al. (2006) for SCORS
Emotional Investment in Relationships (EIR)………………...…155
12. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’,
‘Positive Response’, and Peters et al. (2006) for SCORS
Understanding of Social Causality (USC)…………………….....156
13. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’,
‘Positive Response’, and Peters et al. (2006) for SCORS
Self-Esteem (SE)………………………………………………...157
14. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’,
‘Positive Response’, and Peters et al. (2006) for SCORS
Identity and Coherence of the Self (ICS)…………………….….158
15. Number of Individual Psychotherapy and Medication Patients
Meeting Clinical Significance Criteria for ‘Recovered’ and
‘Positive Response’ for SCORS-C…............................................159
viii

16. Differences in RCI between Psychotherapy and Medication
Treatments………………………………………………………160

ix

I. INTRODUCTION
“All I want to do is to follow the advice given by Elihu, the son of Berachel of old, who said, ‘I
will speak that I may feel relief’; for there is a redemptive quality for an agitated mind in the
spoken word.”
-J.B. Soloveitchik
in The Lonely Man of Faith

Despite serious empirical and clinical questions regarding diagnostic reliability
and validity (Blom, 2003; Boyle, 2002; Whitaker, 1992), the Diagnostic and Statistical
Manual-IV (DSM-IV; American Psychiatric Association [APA], 1994) provides the most
widely accepted diagnostic criteria for schizophrenia. Due to the wide availability of the
DSM-IV only the most essential characteristics of the schizophrenia diagnosis will be
discussed below.
The most characteristic criteria necessary to receive a diagnosis of schizophrenia
are the presence of two (or more) of the following symptoms, each present for a
significant portion of time during a one month period: 1) delusions; 2) hallucinations; 3)
disorganized speech; 4) grossly disorganized or catatonic behavior; and/or 5) negative
symptoms (Criterion A). It is important to note that only one Criterion A symptom is
required if delusions are bizarre, hallucinations consist of a voice keeping a running
commentary on the person’s behavior or thoughts, or two or more voices are conversing
with each other. Bizarre delusions are defined as anything that is entirely improbable. For
example, a young man of twenty-one fears an alien with three heads is tracking his every
movement because his patterns of gesticulation are the key to unlocking the mysteries of
the universe. Importantly, a delusion that is fantastic but possible is not bizarre. For
example, a schizophrenic man of thirty-five fears the FBI is spying on his family. This is
unrealistic but nonetheless possible since the FBI could spy on someone with the
1

appropriate motivation, whereas three headed gumshoe aliens are not in the realm of
possibility.
Characteristic symptoms fall into two broad categories: positive and negative.
Simply, positive symptoms appear to reflect an excess or distortion of normal functions,
whereas negative symptoms appear to reflect a diminution or loss of normal functions.
The positive symptoms (Criteria A1-4) include distortions in thought content (delusions),
perception (hallucinations), language and thought processes (disorganized speech) and
grossly disorganized or catatonic behavior. Negative symptoms (Criterion A5) include
restriction in the range and intensity of emotional expression (flattening), diminishment
of fluency and productivity of thought and speech (alogia), and greatly decreased degree
of goal-directed behavior (avolition).
Concordant with these primary symptoms are distinct and pervasive
social/occupational dysfunction (Criterion B). Continuous signs of the disturbance must
persist for at least six months which must include at least one month of symptoms that
meet Criterion A (Criterion C). The remaining criteria include: exclusion of
schizoaffective disorder and/or mood disorder (Criterion D), exclusion of a substance
abuse or general medical condition (Criterion E), and if there is a history of a pervasive
developmental disorder (e.g., autism) a diagnosis of schizophrenia is made only if
prominent delusions or hallucinations are also present for at least one month (Criterion
F). DSM-IV recognizes 7 subtypes of schizophrenia (Paranoid, Disorganized, Catatonic,
Undifferentiated, Residual, Schizophreniform, and Schizoaffective; see APA, 1994, pp.
286-295).
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Demographically, in the United States (U.S.), the onset of psychosis commonly
occurs between the ages 17 to 27 for males and 20 to 37 for females. In the U.S., race
does not seem to impact the distribution of schizophrenia. Schizophrenia affects 1-1.5%
of the U.S. population and this percentage is consistent worldwide (Silverstein,
Spaulding, & Menditto, 2006). Consistently, schizophrenia is among the top 10 leading
causes of disability in adults both in the U.S. and worldwide, therefore representing a
disorder of significant fiscal importance. In the U.S., nearly 80% of persons with
schizophrenia are unemployed and many of the remaining 20% are significantly underemployed indicating overall a crippling social and vocational condition. In the U.S. up to
13% of people with schizophrenia commit suicide.
Of particular relevance to this study, almost 100% of the people diagnosed with
schizophrenia in the United States have been or will be treated with psychotropic drugs
(Jackson, 2005). A very small percentage of people suffering from this mental illness
receive psychotherapy and an even smaller percentage will be offered psychodynamic
psychotherapy, despite evidence that a variety of forms of psychotherapy are effective for
psychotic disorders such as schizophrenia (Jackson, 2005; Karon, 1989; Whitaker, 1992).
An honest review of the empirical and clinical literature is imperative so that
psychiatry and psychology can develop the most effective treatments for people suffering
from schizophrenia. Such an exploration might inevitably lead to a major transformation
whereby the mental health field can begin speaking about catharsis and recovery, as
opposed to mere management and containment of schizophrenia. The latter pessimism is
a reflection of the non-empirically supported notion that schizophrenia is solely an
irreversible, organic, degenerative brain disease (Harding & Zahniser, 1994; Harman,
3

2003, Siebert, 1999). This unfounded assumption drives medication-only treatments
despite the fact that there are no replicable studies to validate this widely held idea. In
fact, as will be shown, there are a multitude of studies investigating the impact of
untreated schizophrenia, as well as longitudinal outcome studies refuting the degenerative
assumption.
Considering the monolithic medication approach to schizophrenia one would
suspect that ample evidence exists regarding the physiological etiology of this alleged
brain disease. However, laboratory findings diagnostic of schizophrenia are inconsistent
and, more importantly, confounded by the significant physiological side-effects of an
individual’s past and present use of neuroleptic medications (APA, 1994; Harding &
Zahniser , 1994; Harman, 2003; Jackson, 2005; Sullivan, Owen, O’Donovan, &
Freedman, 2006; Warner, 2004). Thus, the idea that schizophrenia is a purely
biologically-derived, degenerative brain disease is “totally unfounded and unsupported by
scientific evidence…Rather the basis of the appellation ‘brain disease’ is based on
theories of possible etiologies of those diagnosed with schizophrenia.” (Harman, 2003, p.
240). The APA-sponsored DSM-IV honestly writes, “…laboratory findings may also be
noted as a complication either of schizophrenia or of its treatment” (APA, 1994, p. 306).
In fact, the side-effects of neuroleptic treatments are so hazardous that the DSM-IV has a
diagnostic category known as “Neuroleptic induced disorders” (APA; pp. 735-805). As
the DSM-IV acknowledges, an additional problem is that there are no replicable studies
identifying the biological correlates of schizophrenia using drug virgins (APA, 1994).
‘Drug virgins’ are defined as individuals free of the damaging and confounding sideeffects of antipsychotic medications. When drug virgin patients are investigated, the
4

results indicate that medications rather than the illness itself are generally responsible for
any brain differences between schizophrenics and normals (e.g., Gur et al., 1998). The
overt contradiction between what is known about schizophrenia and how it is treated
should not be overlooked here. Although the APA-published DSM-IV admits that there
are no studies that document the biological underpinnings of schizophrenia, it is this very
same body that advocates medication as the primary and, in general, sole treatment
approach.
Although some degree of genetic effect is likely present in the development of
schizophrenia, the genetic contribution is undoubtedly non-linear and far more limited
than originally suspected. Harvard geneticist Richard Lewontin (2000) comments on the
neurogenetic reductionism fueling the assumption that genetic variation can explain all
forms of human illness, he writes,
The search for genetic variations is a major preoccupation of medical
research [but]…it is bad biology… There exists, and has existed for a long time, a
large body of evidence that demonstrates that the ontogeny of an organism is the
consequence of a unique interaction between the gene it carries, the temporal
sequence of external environments through which it passes during life, and
random molecular interactions within individual cells. It is these interactions that
must be incorporated into any proper account of how an organism is formed (pp.
17-18; my emphasis).
Indeed, what etiological evidence does exist point to poly-genetic factors of low to
moderate effect in a dose-response, non-linear relationship with a variety of high-risk
environmental factors such as deviant communication between children and caregivers
5

(Wynne & Singer, 1963), disturbed interactions within a family (Alanen, 1980, 1997;
Tienari et al., 1985), childhood trauma (Read, Perry, Moskowitz, & Connolly, 2001;
Read & Ross, 2003), and prenatal and perinatal factors (Gilmore & Murray, 2006).
Thus, assumptions regarding the linear biological or genetic correlates of schizophrenia
are, at least for now, empirically and theoretically untenable. Koehler (2006) more
concisely describes the complex thinking needed if we are to develop a more
sophisticated view of schizophrenia development and treatment,
…reductionism in psychiatry is what it has always been, a costly and erroneous
shortcut to the comprehensive understanding and treatment of complex mental
disorders which arise from complex non-linear interactions between genes, brain,
mind (which included multiple factors at the level of the individual and the
family), as well as the socio-cultural surround…(p. 3).
By taking seriously the disconnect between how little is known about the etiology of
schizophrenia and the rigid certainty with which medical treatments are offered, it is the
stated intention of this dissertation project to arrive at an empirically and theoretically
sober understanding of current psychotherapeutic and psychopharmacological treatment
practices. This will be accomplished by investigating five interrelated sections.
Section I: Emil Kraeplin, Degeneration Theory, and Philosophical Realism. Since
neuroleptic treatments overwhelmingly dominate the modern treatment approach for
schizophrenia, it is helpful to understand the epistemology of the schizophrenia construct
that continues to impact biological conceptualizations and treatment decisions. This
section will focus on two of the non-epistemic philosophical underpinnings of the

6

schizophrenia construct originally developed by the founding father of modern psychiatry
Emil Kraeplin: degeneration theory and philosophical realism.
Section II: The Empirical Validity of the Degenerative Disease Construct.
Philosophical deconstruction of a prevailing construct does not invalidate its core
assumptions. That is, simply because modern biopsychiatric conceptions of schizophrenia
are substantially influenced by a multitude of non-epistemic factors does not necessarily
mean that the illness is not biologically-based and degenerative. That being said, if the
biopsychiatric notion that schizophrenia is a chronic degenerative brain disease resulting
in a psychotoxic impact on the brain is accurate, then naturally most if not all cases of
schizophrenia (treated and untreated) would ultimately leave a person significantly
incapacitated ad infinitum. After all, biological medication treatments are only designed
to slow this allegedly inevitable process and mask rather than cure the most striking
features of the illness (i.e., positive symptoms such as hallucinations). To determine the
validity of the degenerative/psychotoxic assumptions of biopsychiatry, I will review two
interrelated empirical questions: 1) does the duration of untreated schizophrenia predict
greater severity of illness, poorer overall outcome, and psychotoxic brain damage; and 2)
are there longitudinal studies that report any degree of significant improvement or
recovery for persons diagnosed with schizophrenia?
Section III: The Effectiveness and Safety of Neuroleptic Medications. For the
reason that neuroleptic medications are used as the frontline - and usually only treatment of schizophrenia (Breggin, 1991; Karon, 1989; Whitaker, 2002, 2005), it is
imperative to summarize the empirical literature that has investigated the effectiveness
and safety of these medications. The effectiveness of neurolepetc medications will be
7

evaluated on four fronts by: 1) presenting data regarding the effectiveness of older
(typical) and newer (atypical) neuroleptic medications (Table 1 lists all of the
medications still commonly used to treat schizophrenia; Appendix A 1 ); 2) presenting a
critique of the methodological limitations inherent in the Food and Drug Administration
(FDA) and non-FDA randomized control medication trials (RCT) specific to
schizophrenia research 2 ; 3) summarizing the most recent, large-scale, naturalistic study
investigating the comparative effectiveness and safety of the newer versus older
neuroleptic drugs; and 4) presenting the variety of side-effects resulting from exposure to
typical and atypical neuroleptic medications.
Section IV: The Effectiveness of Psychodynamic Psychotherapy of Schizophrenia.
This section will explore the empirical effectiveness of the psychodynamic treatment of
schizophrenia. There is a growing body of empirical and theoretical literature of effective
non-psychodynamic approaches to schizophrenia (e.g., cognitive-behavioral therapy) that
will not be addressed here. Focus on psychodynamic treatment will be primary because
this is the modality used by the therapists that treated the patients in the empirical
component of this dissertation project.
Section V: Pre- to Post-Treatment Change in the Object Relations of
Schizophrenic Patients. Data for this project were generously provided by the Michigan
State Psychotherapy Project archives (Karon & Vandenbos, 1981). The empirical section
of this dissertation project applies a modern measure of object relations to pre- and posttreatment Thematic Apperception Test (TAT; Murray, 1943) narratives of schizophrenic
1

All tables are located in Appendix A
The critique presented below is not intended to be a general critique of RCT methodology. Rather, it is a
critique specific to the methodology of schizophrenia drug research.

2
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patients divided into two groups: 1) individual psychodynamic psychotherapy without
medication (Psychotherapy; n = 9); and 2) routine medication-only (typical neuroleptics
only) treatment (Medication; n =12) to determine clinically significant treatment effects
within- and between-groups. That is, it is the primary purpose of this study to investigate
two particular research questions: 1) can individual psychodynamic psychotherapy for
schizophrenia - without any medication - result in positive outcome in terms of object
relations; and 2) what is the comparative effectiveness of medication-only versus
individual psychodynamic psychotherapy-only treatment of schizophrenia?
The experimental design utilized in the original study conducted by Karon and
Vandenbos (1981) called for the selection of schizophrenic patients to be assigned on the
basis of a random number table to one of three treatments: 1) psychotherapy without
medication (Psychotherapy-only A); 2) psychotherapy with adjunctive medication
(Mixed B); and 3) routine hospital treatment consisting primarily of phenothiazines (i.e.,
typical neuroleptics; Medication-only C). The adjunctive medication provided to
individuals of the Mixed Group (B) was discontinued after the first few weeks of the
study. Overall, 36 patients were evenly distributed among the three treatment groups.
Due to incomplete data for the Mixed group (B) this cohort has been removed from the
current study. Although this is an unfortunate loss of potentially useful and interesting
data, the primary and unique aspect of the current experiment is the assessment of a
completely non-medicated group. That is, while there are studies exploring mixed
treatment approaches (see Gottdiemer & Haslam, 2002) there are, as far as could be
determined, no published U.S.-based studies in the last 25 years that utilize a fully nonmedicated group.
9

Karon and Vandenbos’ (1981) administered four assessment instruments
measuring patients’ thought disorder and two personality projective instruments at preand post-treatment to all patients. Number of days spent in the hospital and a blindly
rated clinical status interview were also used as measures of outcome. At the conclusion
of their 20-month investigation researchers found that patients receiving psychotherapy
(Groups A & B) significantly outperformed individuals receiving medication-only
(Group C) on three of the four instruments assessing patients’ thought disorder, on the
clinical status interview, and number of days spent in the hospital due to mental
dysfunction. On the fourth measure of thought disorder differences between the
psychotherapy and medication-only patients nearly reached significance (p = .07), again
favoring the psychotherapy patients. Individuals of the medication-only group did not
fare better in any area assessed.
One of the two measures for which there was no significant finding was the TAT.
During the time period Karon and Vandenbos collected and reported their findings there
were no reliable and valid narrative measures to adequately assess TAT protocols. In lieu
of a reliable and valid measure Karon and Vandenbos applied a global score to pre- and
post-treatment TAT protocols to assess general health-sickness in a manner akin to the
three Axis V scales described in the DSM-IV (APA, 1994). As a result, they were unable
to fully tap the information inherent in the pre- and post-treatment TAT protocols. This
study corrects this original deficiency by using Westen’s reliable and valid Social
Cognition and Object Relations Scale (SCORS; Westen, 1995; Hilsenroth, Stein, &
Pinsker, 2004) to score the original pre- and post-treatment TAT protocols for both
groups.
10

The SCORS was used to measure the object relations and social cognitive
functioning of patients from their pre- and post-treatment TAT protocols. Westen and
Gabbard (1999) defined object relations broadly as a person’s enduring patterns of
interpersonal functioning in intimate relationships, beginning - but not concluding - with
the mother/infant dyad. Therefore, object relations are the interpretation and mental
internalization of relationships between the self and other people or objects (i.e., places,
things, constructs). As Summers (1994) states, “[T]he structure of the self is formed from
the internalization of early attachment relationships and is based on the symbolic
meaning the child gives to its early object ties. In this sense, these early object relations
not only endure, but define the sense of self and influence later relationships with others”
(p. 350). As will be shown throughout this dissertation project, schizophrenia is far more
than a biochemical illness defined by disturbed visual and auditory perceptual processes.
Rather, it is a mental disorder driven by core disturbances in a person’s capacity to relate
to his or her self and others; and, even the most bizarre of the psychotic hallucinations
and delusions, as well as massive social isolation common to schizophrenic patients, are
best understood in the framework of a grave interpersonal disturbance. As such,
measuring an individual’s object relations pre- and post-treatment is essential to assessing
the degree and quality of therapeutic relief provided by any given treatment.
The SCORS is a narrative-based object relations measure designed to assess a
variety of dynamic personality features beyond the overt symptomatic presentation of the
patient (see Methods below). As far as can be discerned from the extant literature, the
current investigation was the first to apply the SCORS to a strictly schizophrenic sample,
thus providing important reliability and validity information for a psychotic population.
11

Assessing observer-rated object relations adds incrementally to the overwhelming
majority of the schizophrenia outcome literature that are generally limited to assessment
of overt psychiatric symptoms and/or drug tolerability (e.g., Lieberman et al., 2005).
Furthermore, the current analysis is unique to the extant literature in that it uses an
experimental design that includes a fully non-medicated group. Such studies are
relatively rare and generally considered irresponsible “malpractice” (Karon, 2003, p. 96)
due to the non-empirically supported assumption that medication treatments are the only
viable treatment for schizophrenia (Bola, 2006). In fact, despite considerable counterevidence to be provided below, the schizophrenia Patient Outcome Research Team
(PORT; Lehman & Steinwachs, 1998) referred to psychodynamic psychotherapy as
“harmful” for patients suffering with schizophrenia (p. 8). The PORT is regarded as one
of the authoritative voices in the treatment of schizophrenia and its conclusions are
accepted as empirical fact despite its evident distortion of the psychodynamic treatment
literature (see for a critique of the PORT Gottdiener & Haslam, 2003; Silver, 2003; ver
eecke, 2003). Considering the PORT study’s comments neglectful of available empirical
evidence, hypotheses for the current study include: 1) The SCORS will exhibit
satisfactory reliability and validity for use with a strictly schizophrenia sample; 2)
Psychotherapy-only patients will not clinically regress, rather, they will exhibit clinically
reliable improvement in their object relations; and 3) the object relations of the
Psychotherapy-only patients will exhibit significantly greater clinically reliable change
compared to the Medication-only patients due to psychodynamic psychotherapy’s
explicit emphasis on past and present interpersonal functioning.

12

Section I: Emil Kraeplin, Degeneration Theory, and Philosophical Realism
Emil Kraeplin, born in 1856, is considered the father of modern descriptive
psychiatry and founder of the ‘dementia praecox’ concept that was later changed to what
we now term ‘schizophrenia’ (Bleuler, 1911). Kraeplin’s professional life was committed
to the classification of mental phenomena. His nosological thinking focused almost
exclusively on the relationship between manifest symptoms and the developmental
course and outcome of mental disorders. Kraeplin’s ideas are still highly influential today
(Gottesman, 1999; Harman, 2003).
Kraeplin required an overarching organizing principle with which to ground his
observations, a principle that would provide a classificatory framework useful for
categorizing the complexity of observed mental phenomena. He had little to draw on
from previous research since psychiatry itself had only existed as a medical profession
since the 1850s (Gottesman, 1999). In fact, the first three editions of his masterwork,
Compendium der Psychiatrie, made only incremental contributions to the field of
descriptive psychiatry and they were received indifferently by the psychiatric
establishment of the time. However, Kraeplin’s fourth edition published in 1893 made the
first imprint of what would become a lasting mark on modern psychiatry.
In this fourth edition, Kraeplin operationalized a unique organizing principle to
ground his observations of a wide array of mental phenomena: the syndrome-course unit
Blom (2003). Adoption of this umbrella notion allowed Kraeplin to distinguish symptom
clusters with a relatively good outcome from those with a poor outcome. As such, he
introduced outcome as a diagnostic criterion. As will be seen, this move certainly had
practical advantages for his capacity to organize ever-greater numbers of mental
13

phenomena, but was void of empirical backing and beholden to a variety of nonepistemic assumptions that have profoundly shaped the modern biopsychiatric conception
of schizophrenia.
The term ‘dementia praecox’ first appeared in the fourth edition of Kraeplin’s
Compendium in 1893. This publication is considered the birth of the modern
schizophrenia concept. Using the notion of the syndrome-course unit, Kraeplin
categorized dementia praecox under the heading, ‘mental degenerative processes’,
thereby suggesting that its outcome was inherently poor. On what basis did Kraeplin
make this classification? This is a question often left unanswered despite its monumental
significance for contemporary research and treatment strategies. In his postmodern
deconstruction of schizophrenia, Blom (2003) attempts to answer this question by
assessing the role of degeneration theory in Kraeplin’s thought, he writes,
Degeneration [theory] referred to a supposed hereditary predisposition to all kinds
of misery, such as physical and mental disease, addiction, moral decay, sexual
aberrations, and criminal behavior. In Kraeplin’s view, mental disorders
originated from some inherited degenerative trait or from an external cause - or
possibly from both (p. 55).
In Kraeplin’s writings, “external cause” was meant to capture the effects of brain trauma,
epidemics, pre-natal trauma, etc. That is, they were not meant to reflect the vicissitudes of
psychosocial life, a factor Kraeplin seemed to deem generally irrelevant. As is evident in
Kraeplin’s primary writings, he organized almost all mental phenomena based on 19th
century degeneration theory though he never explicitly stated this as such. Rather, he
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cited the more scientific sounding ‘syndrome-course unit’ as his primary organizing
principle.
In the 19th century, degeneration was deemed the polar opposite of successful
social and physical evolution. Kraeplin borrowed heavily from the degenerationist idea
that certain patterns of the brain were remnants of our ancient evolutionary past or in
Kraeplin’s words, “tribal history” (as cited in Blom, 2003, p. 75). Degeneration theory
argues that such maladaptive patterns manifest as regressive cognitive and behavioral
functioning. As Blom (2003) notes, this theory held wide appeal in 19th century Europe
because it gave society a framework for explaining modernity’s budding “misfortunes
and wickedness” (p. 75). Anthropologist R. Barrett’s (1996) comments illuminate the
prolific nature of degenerationist ideas in Europe at this historical moment,
Thus in their physiognomy and behaviour [sic], criminals and the insane were
likened to primitives… The urban poor, including prostitutes, criminals, and other
immoral types, were degenerates, exemplified by their low brain weights,
protruding jaws, and misshapen skulls… Degeneration theory had to do with the
proper place of races and classes… Most importantly, it was used to explain the
apparent increase in the rates of mental illness and incurability… (p. 67).
Kraeplin’s enthusiasm for degenerationist thought was translated into an uncritical use of
this non-epistemic construct throughout the development of his dementia praecox
concept (Blom, 2003). For example, Kraeplin observed, “About 75% of the cases that go
to mental asylums appear to reach the higher grades of dementia. The patients gradually
sink deeper and deeper, become dull and apathetic and lose all understanding for those
around them” (1899, p. 117). These observations led Kraeplin to consider schizophrenia
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as degenerative in nature. Unintentionally, Kraeplin’s a priori commitment to the
biological notion of degeneration prevented him from considering the effects of isolation,
maltreatment, the cruel experimental treatments frequently used in the institutions of the
19th century, and the social stigma insane people endured at the time (Gilman, 1982), all
of which undoubtedly affected clinical course. Despite the fact that Kraeplin himself
observed that between 13-20% of these patients improved almost completely, he still
spoke monolithically of a degenerative trait inherent in schizophrenia. Kraeplin could not
explain this phenomenon of recovery. Interestingly, modern psychiatry has found a
solution to Kraeplin’s dilemma by often dismissing improved and recovered patients as a
result of misdiagnosis (Karon, 2003; Whitaker, 1992). That is, if a person with
schizophrenia exhibits significant improvement, today or yesteryear, it is assumed that
they were never truly schizophrenic because, the circular logic concludes, schizophrenia
is a degenerative disease. Such contemporary proclamations indicate the degree to which
Kraeplin’s degenerative emphasis has remained.
As can be seen from the above discussion, prior to philosophical post-modernism
it was uncommon for scientists to introspect about non-epistemic influences informing
their work. After all, science, unlike religion and philosophy, was deemed a mode of
investigation exempt from external contaminants and conceived as ‘truly objective’. Such
thinking formed the basis of Kraeplin’s nosological creations and by default allowed him
to feel confident that dementia praecox existed completely independent of his chosen
organizing principles (i.e., syndrome-course unit and degenerative thought). Thus,
Kraeplin deemed his description of individuals suffering with dementia praecox as a
purely objective, in-the-world natural phenomenon open to scientific discovery. In
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Hegelian terms, Kraeplin ‘removed himself from history’ and was able to see the world
as it ‘truly’ exists. This is best known as philosophical realism and it too has had a
profound impact on modern biopsychiatric conceptions of schizophrenia (Blom, 2003).
Philosophical Realism and Kraeplin’s Dementia Praecox Construct
Reliance on a realist position reifies schizophrenia as a natural disease entity that
allegedly exists independent of the observer. A consequence of this in daily practice is
the location of schizophrenia as a phenomenon to be examined outside the ebb and flow
of common human experience and this has contributed to the suspension of curiosity in
regard to the psychosocial and mentalized aspects of schizophrenia.
Positioning the observer outside the schizophrenic experience, whether the
observer is a researcher or practitioner, accomplishes a few things. First, a concretized
professional-patient hierarchy is constructed within which information flows unidirectionally. Unto itself the professional-patient hierarchy is not detrimental and will of
course exist in a situation when one person (the patient) seeks professional assistance
from a trained other (psychotherapist, psychiatrist, etc.). However, it is my assertion that
in the biopsychiatric model the doctor/schizophrenic split is hypertrophied due to its
epistemological relationship to degeneration theory. That is, the patient is perceived as
wholly different due to an inherent, archaic defect and the gap between schizophrenic
patient and doctor will only widen as the degenerative trait runs its inevitable course. At
best, this concretized hierarchical relationship results in the benevolent transmission of
sympathy and basic human concern for the welfare of a suffering other. Yet, this
hierarchy can also result in an institutionalized, unilateral mandate for compliance to en
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vogue treatments. Modern mental health strategies for schizophrenia are a combination of
these two outcomes, with an unfortunate emphasis on the latter as seen in many
community agencies, day care treatment facilities, and group homes that impose
medication compliance as a prerequisite for participation in their services (Karon, 2003).
Medication non-compliance is interpreted as a ‘lack of insight’ on the part of the sufferer
and is considered symptomatic of schizophrenia itself, rather than an expression of a
person’s discomfort with side-effects, lack of drug effectiveness, or his or her demand to
be treated as a person with a story to tell. In this sense, the schizophrenic person is
regularly considered alien from prototypical insight common to the non-schizophrenic
‘normal’. A person suffering with schizophrenia is viewed as lacking sentience and
judgment - two definitive aspects of human-ness (Whitaker, 1992). The real-world
consequence of this concrete split is that the schizophrenic is typically not considered
integral to the development or modification of treatment strategies due to their assumed
lack of insight.
It is essential to note that the push for current medication compliance should not
be interpreted as pure malevolence. Rather, it is an expression of the basic suppositions of
biopsychiatry and is undoubtedly a well-meaning attempt by the majority of practicing
psychiatrists to alleviate real human suffering. As such, it is all the more important for
psychiatrists to understand the philosophical roots driving their clinical recommendations
in order to develop the best possible approach to schizophrenic suffering. Understanding
the realist underpinnings of biopsychiatric thought better equips one to comprehend the
primacy of current neuroleptic treatment strategies. After all, if the origin of madness is
genetic, internal to the sufferer from birth and is disconnected from the impact of human
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interactions, then there is no reason to consider any treatments other than biologicallyoriented ones. Further, and of particular relevance to this dissertation project, if a
schizophrenic lacks the capacity for insight and is excluded from treatment decisions in
general, psychodynamic psychotherapy will be the first to be labeled useless and
ineffective. Indeed, marginalization of psychodynamic psychotherapy for the treatment of
schizophrenia has been made official by the schizophrenia PORT recommendations
(Lehman & Steinwachs, 1998) and others (Drake & Sederer, 1986), despite the lack of
empirical backing for such assertions (Gottdiener & Haslam, 2002; Karon, 2003; ver
Eecke, 2003).
In concluding this philosophical section, Blom (2003) asserts that if current
treatment approaches are to prove effective we must come to appreciate that the
biopsychiatric notion of schizophrenia is “embedded in a matrix of scientific
assumptions… guided by various culture-religious themes which dominated psychiatric
thinking at the time [of its development]…and [has been] applied rather uncritically
within the field…” (p. 9). Others have similarly investigated the scientific immaturity of
the schizophrenia construct (Barrett, 1996; Bentall, 1998; Boyle, 2002; Warner, 2004).

Section II: The Empirical Validity of the Degenerative Disease Construct
If schizophrenia is a chronic, degenerative brain disease then naturally untreated
schizophrenia would ultimately leave a person significantly incapacitated or dead. That
is, for people suffering with schizophrenia it would be impossible to evidence signs of
recovery. This is the idea driving the ‘management rather than catharsis’ strategy of
medication treatments. However, what does the empirical literature have to say in regard
19

to the degeneration assumption? The answer can be found by asking two interrelated
questions: 1) does the duration of untreated schizophrenia predict psychotoxic brain
damage and/or poorer overall outcome as insisted by biopsychiatry; and 2) are there
studies exhibiting any degree of significant improvement or recovery for persons
diagnosed with schizophrenia?
Duration of Untreated Schizophrenia: Psychotoxicity and Clinical Outcome
Based on the biopsychiatric assumption that schizophrenia is a degenerative brain
disease, biopsychiatry has concerned itself with the potential negative consequences of
not treating schizophrenia as soon as possible. More specifically, it is a widely held belief
that there is a “potential for untreated psychosis to be toxic to the brain” (Ho et al., 2003,
p. 142). ‘Untreated psychosis’ is defined as the interval from first psychotic symptom to
first treatment received. This question is very important to the main question of this
dissertation project because the idea that psychosis left untreated by medications results
in psychotoxic effects has raised ethical questions regarding the use of placebo controls
in experimental drug trials (Craig et al., 2000). Similarly, and quite pertinent to this
dissertation project, this notion has made inclusion of un-medicated schizophrenics in
psychotherapy outcome studies subject to professional scorn and open to allegations of
malpractice (Bola, 2006; Harman, 2003; Karon, 1989, 2003). Therefore, empirical
resolution of this hypothesis is necessary for opening up new areas of psychotherapy
research and expanding our perspective beyond a medication-only treatment approach.
Using structured interviews with schizophrenic patients and their families, as well
MRI scan measurements, Hoff and colleagues (2000) found no significant correlations
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between duration of untreated schizophrenia and severity of either cognitive or structural
brain deficits. The authors conclude that an “uncontrolled toxic brain process [is an]
unlikely” explanation of schizophrenic suffering (p. 1824).
Using a variety of clinical measures to assess positive and negative psychotic
symptoms, hopelessness, depression and anxiety, Craig and colleagues (2000) found that
the duration of untreated schizophrenia was not significantly associated with severity or
course of illness. In fact, the only statistically significant finding suggests that the earlier
neuroleptic drugs are given, the more disturbed is the course and severity in regard to
anxiety and depression. The authors conclude, “…our results failed to support the
contention that a longer exposure to psychotic symptoms per se leads to a worse clinical
outcome…[and]…do not support the suggestion of a psychotoxic effect exerted by
prolonged exposure to psychosis” (p. 66).
Utilizing advanced neurological measurement devices, Ho and colleagues (2003)
found no significant correlation between length of untreated schizophrenia and
neurocognitive functioning, brain volumetric measurements, or surface anatomy
measurements. The authors conclude, “[Our results] suggest that large-scale initiatives 3
designed to prevent neural injury through early [medication] intervention in the prepsychotic or early psychosis phase may be based on incorrect assumptions” (p. 142).
Perkins, Gu, Boteva and Lieberman (2005) performed a meta-analysis of fortythree studies that investigated the impact of the duration of untreated schizophrenia. The
3

David (2004) addresses the economic and clinical wisdom of early, large-scale medication initiatives
proposed by pharmaceutical companies. He states, “From a dispassionate appraisal of the research literature
on the treatment of schizophrenia…If an early intervention service is to be useful, it should be at the
population level, free of side-effects and inexpensive, and should not undermine clinical practice” (e.g.,
medication effects causing brain damage that makes quality, continuous treatment less effective and less
probable; p. 111).
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results of this meta-analytic study found no association between untreated schizophrenia
with neurocognitive deficits or morphological changes in the brain, therefore refuting the
idea that schizophrenia is a degenerative brain illness that has psychotoxic effects on the
brain. Further, this meta-analysis did not bear out support for early medication
intervention strategies since it found no association between the duration of untreated
schizophrenia and symptom relapse.
In their own review of the literature investigating the impact of the duration of
untreated schizophrenia, Segarra and colleagues (2006) call for a redefinition and
reconsideration of the assumptions that the duration of untreated schizophrenia
deleteriously impacts clinical course, outcome, and brain structure. Based on this
redefinition, the authors suggest that the design of early intervention programs reflect a
heterogeneous rather than medication-only approach.
Ayres and her Brazilian colleagues (in press) recently explored the impact of the
duration of untreated schizophrenia in a large-scale São Paulo study. Using cognitive
tests to assess working memory, attention, and verbal fluency of patients with first-onset
schizophrenia the authors found no correlation between the duration of untreated
schizophrenia and cognitive deficits.
Of course, there are studies that find a relationship between the duration of
untreated psychosis and clinical outcome (e.g., Clarke et al, 2006). After all, a person left
to suffer without intervention – whether psychotherapy, medication, or both – may of
course regress emotionally, though physiological damage appears unlikely. However, the
majority of empirical evidence, including meta-analyses, refutes the
degenerative/neurotoxic position. Rather, clinical regression is more likely to be
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indicative of the existential, vocational, interpersonal and social alienation resulting from
the onset of a frightening schizophrenic condition, rather than the supposed neurotoxiciy
of schizophrenia without medication treatment (Karon, 2003). Concerning the neurotoxic
assumption McGlashan (2006) asks and replies,
[Does active psychosis] engineer brain cell death and deterioration? This
hypothesis is currently popular as an explanation of the duration of untreated
psychosis effect in early schizophrenia. The clinical and neurobiological evidence
for its validity is…found wanting (p. 609).
If anything, research is far more supportive of the idea that any significant neurological
damage associated with schizophrenia is likely related to the medications used to treat the
illness rather than the illness itself (APA, 1994; Breggin, 1991; Jackson, 2005; Whitaker,
2002, 2005).
Taking all this into consideration, it becomes all the more pressing to design
early-intervention strategies based on research of all possible short- and long-term
treatments (e.g., Alanen, 1997), rather than the false and draconian assumption that not
using medications is psychically and organically destructive. That is, it is a primary,
though false assumption of biopsychiatry that not administering drugs immediately is
malpractice (Bola, 2006; Breggin, 1991).
Of course, altruistically, psychiatrists want to minimize the subjective suffering of
a person suffering from distressing symptoms. This is often stated as a further
justification for the heavy reliance on psychiatric drugs, especially in the early period of
the illness when the symptoms are particularly acute and disturbing for all involved.
However, it is also false that only drugs can quickly minimize acute psychotic symptoms
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such as frightening hallucinations and disorienting delusional constellations (Alanen,
1997; Irwin, 2004a; Karon & Vandenbos, 1981; Harding & Zahniser, 1994; Paul, Tobias,
& Holly, 1972; Paul & Lentz, 1977). Most recently, research emanating from the
Scandanavian research of Alanen (1997) and Seikkula and colleagues (2000, 2003) speak
to the empirical and clinical effectiveness of psychological intervention for early and
acute positive symptoms with little to no use of neuroleptic medications.
This entire discussion is relatively moot if there is little in the way of counterevidence suggesting that there is real, long-term hope for people suffering from
schizophrenia. A look at the body of longitudinal schizophrenia outcome studies adds
additional empirical evidence that schizophrenia is not a chronic, progressively
degenerative brain disease leaving such people without hope.
Hope or Dread: Longitudinal Studies of Schizophrenia
International and U.S.-based studies have investigated the degenerative
assumption and they have found significant heterogeneity of outcome with a variety of
received treatments (e.g., psychotherapy and medication) and even without treatment. I
will provide an illustrative summary of the longitudinal evidence, but for the interested
reader more extensive summaries of the longitudinal literature are available elsewhere
(Leff, Sartorius, Jablensky, Korten, & Ernberg, 1992; Harrison et al., 2001; Hopper,
Harrison, Aleksander, & Sartiorius, 2007; Hopper and Wanderling, 2000; Jablensky et
al., 1992; Menezes et al., 2006). To more clearly understand the studies presented below
it is important to hold in mind the operational definition of ‘recovery’ imparted by
Harding and Zhasiner (1994) based on their summary of the longitudinal evidence,
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The universal criteria for recovery have been defined as no current signs and
symptoms of any mental illness, no current medications, working, relating well to
family and friends, integrated into the community, and behaving in such a way as
to not being able to detect having ever been hospitalized for any kind of
psychiatric problems (p. 141).
Clearly, the working definition of ‘recovery’ used in the following studies to which I will
now turn is quite strict and highly relevant to day-to-day functioning.
In 1968, Murphy and Raman (1971) relocated 89 of 90 first-episode
schizophrenics, admitted twelve years earlier to a hospital in the developing country of
Mauritius. Patients and a person close to them throughout the intervening years were
interviewed to determine current mental state and whether any relapses had occurred.
Despite the fact that no neuroleptics were used in this developing nation at the time, 64%
of the subjects were found to be currently free of symptoms of any kind. Of these 64%,
only 8% went on to experience an additional psychotic episode at some point. Not only
did the lack of early medication do no harm to these patients, this fact might actually help
explain why these relatively low relapse rates are superior to relapse rates in the
developed world where neuroleptics are widely used (Hopper, Harrison, Aleksander, &
Sartiorius, 2007; Irwin, 2004a; Menezes et al., 2006; Warner, 1985).
Following discharge from a psychiatric hospital, Bleuler (1978) maintained
contact with 208 of his schizophrenic patients for 23 years in Zurich, Switzerland. In his
analysis of first-admission patients 23% had achieved full recovery, 43% were
significantly improved, and 34% had little to no change. Although Bleuler unfortunately
did not provide statistical results across treatment interventions, his treatment approach
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minimized the use of biological treatments and strongly favored psychosocial approaches
for those patients he followed clinically.
Tsuang, Woolson, and Fleming (1979) reported on 186 of 200 people admitted to
an Iowa psychiatric hospital between the years 1934 and 1944. Structured interviews
were completed with the patients and a first-degree relative of each. This study reported
that 20% of the patients had little or no psychopathology at follow-up, 26% had mild
symptoms but were generally doing well; and 54% had severe symptoms. Of the studies
being reviewed this one provides the most pessimistic results and yet it still refutes the
idea that schizophrenia is a progressively degenerative disease since almost half of the
patients fared quite well after 35 years.
Huber, Gross, Schuttler, & Linz (1980) reported follow-up results on 502 first
admissions diagnosed with schizophrenia in the 1950s. Face-to-face interviews were
done with each patient. After an average of 22 years 22% had achieved a full recovery;
43% were described as recovered with no psychotic symptoms; and 35% still endured
characteristic schizophrenia symptoms. Were maintenance neuroleptics predominantly
responsible for these positive results? The authors report that this was not the case. In
fact, all of the individuals assessed to be among the healthiest 22% were not receiving
neuroleptic medications.
Ciompi (1980) published approximately 37-year follow-up data for 289 first
admission schizophrenic patients in Switzerland from 1900 onward. He found the course
of the disease to be highly variable based on two hours of interviews with former patients
and information received from family members and hospital files. He found that 27% had
achieved a complete remission and 22% had only residual, non-psychotic symptoms.
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That is, there is at least a 50/50 hope for successful outcome. The idea that schizophrenia
is degenerative - and even more rapidly degenerative without neuroleptics - is specifically
unsettled by Ciompi’s findings because more than 50% of the people in his cohort were
diagnosed before the invention of any modern neuroleptic treatments. Ciompi concluded
that the course of illness is most significantly impacted by “the expectations of the patient
himself, his family, and surrounding persons which… seem often to act strongly as selffulfilling prophecies” (cited in Irwin, 2004a, p. 58)
In contrast to the poor outcome predicted by the biopsychiatric conceptualization
of schizophrenia, Harding et al. (1987a, 1987b) found that the course of schizophrenia is
significantly heterogeneous even for allegedly treatment-refractory, severely chronic
schizophrenics. The authors provide long-term outcome data for 82 of 118 patients who
were alive and interviewed 20-25 years after their entry into a Vermont psychosocial
treatment project for chronic schizophrenia. In the mid-1950s when patients became part
of the study, all of them were chosen to participate in a unique psychosocial rehabilitation
program designed for patients previously deemed resistant to medication and other
biological treatments. In fact, these were classic ‘back ward’ patients usually given-up-on
as hopeless. Severity and chronicity is attested to by the fact that at the initiation of the
rehabilitation/longitudinal study, the average patient had been ill for 16 years, was totally
disabled for an average of 10 years, and had been continuously hospitalized for six years.
Following the psychosocial rehabilitation program they were released to the community
in the mid-to-late 1950s.
Interviews with participants and people close to them, as well as self-report and
observational data measuring positive and negative symptoms, hospital records, social
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and vocational functioning, number of hospitalizations, and overall quality of life, were
all used to assess each patient’s current status. Harding et al. (1987a, 1987b) found that
45% of the participants had no psychiatric symptoms and another 23% had some
psychiatric symptoms, but none that were of a psychotic nature. That is, an astounding
78% of the once biological treatment resistant, chronic, back ward patients fared very
well 20-25 years later. The authors point to the comprehensive rehabilitation program as
a potential reason for the success of 78% of this cohort. They specifically highlight the
clinical utility of “…a pervasive attitude of hope and optimism about human potential,
through the vision that, if given the opportunity, persons with mental illness could
become self sufficient” (DeSistro, Harding, McCormick, Ashikaga, & Brooks, 1995,
cited in Irwin, 2004a, p. 59).
Ogawa and colleagues (1987) followed 140 people diagnosed with schizophrenia
for 21-27 years. The study was designed as a relapse prevention study emphasizing
neuroleptic treatment. At follow-up 31% of the 98 people researchers were able to track
down were completely free of positive symptoms. The authors failed to report other
significant areas that would speak to overall functioning, such as social and vocational
functioning and negative symptoms. At follow-up, 65% of the patients were still taking
neuroleptics and the suicide rate was a relatively high 11%, suggesting that this
neuroleptic-only cohort did not fare favorably to other cohorts with less (or no)
neuroleptic use.
Harding (1995) summarized five U.S. and international longitudinal studies that
followed schizophrenics for no less than 25 years. The authors found that 30% fully recovered
in the long run and that 60-70% became self-sufficient. Importantly, results indicated no
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further improvement in outcome since the introduction of neuroleptic medication. To the
contrary, the long-term evidence suggests that outcomes have deteriorated since the
introduction of medication-only clinical practices (Whitaker, 2002, 2005). In this regard,
Harding (1995) made a startling observation: all of the patients who fully recovered were
among the 50% of the original sample who reported to have stopped taking their medication.
This could suggest that either the higher functioning patients felt freer to discontinue their
medications - though this is not supported by the neuroleptic side-effect or outcome literature
(Breggin, 1991) - or, more likely, that medication may preclude full recovery.
Kua and colleagues (2003) published results of a 20-year longitudinal study
carried out in Singapore. In this cohort, 44% of the participants were found to be in good
to excellent psychological condition as measured by a global assessment scale. Of the
total subject pool 48% were not receiving any neuroleptic medication and all of the 28%
of the subjects with the highest level of functioning were among those not using
neuroleptics.
Menezes and colleagues (2006) reviewed 37 studies with a total of 4100 patients
and a mean follow-up period of 35 months. Assessing a multitude of variables (e.g.,
country of study, psychosocial rehabilitation, age), they found that the sole use of
neuroleptic medications was associated with worse outcome, whereas a combination
approach (i.e., medications plus psychosocial rehabilitation) was a predictor of positive
outcome. Unfortunately, psychotherapy-only treatments were not analyzed.
Results of the World Health Organization (WHO) studies are extensively reported
elsewhere (Harrison et al., 2001; Hopper et al., 2007; Hopper and Wanderling, 2000;
Jablensky et al., 1992) and only a brief summary will be provided here. These studies
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compare longitudinal outcome data in developed versus developing countries, using
results from 2, 5, 15, and 25 years of follow-up data. The generally positive outcomes of
people with schizophrenia in these studies provide additional evidence refuting the
degenerative brain disease assumption. Importantly, the WHO-sponsored studies all used
the same standardized outcome measures thus making the results highly generalizable.
Quite pertinent for this dissertation project, the identical assessment methods provide
fascinating data regarding the potential role of neuroleptic medications in the less
favorable outcomes of the richer and allegedly more clinically advanced nations.
In sum, 38% to 48% schizophrenic participants recovered across geographic
locales. In poorer developing countries, participants were two to three times more likely
to have good clinical outcomes. In regard to vocational functioning, people in poorer
developing nations were three to four times more likely to be holding down a job
(Hopper & Wanderling, 2000). Suicide rates were higher in the economically richer,
more medication-reliant countries to the point that Harrison and colleagues (2001)
recommend special suicide prevention programs be established in the richer developed
nations. Follow-up research revealed that the poorer countries used significantly less
medications (Jablensky et al., 1992). A striking example of the potential negative effects
of medication is seen when comparing Agra, India to the far richer Aarhus, Denmark. In
Agra, outcomes revealed that 63% of the participants had experienced complete
remission, compared to only 17.5% in Aarhus.
Thus, based on these international and U.S.-based longitudinal studies, the DSMIV statement (p. 282) reflecting a main supposition of biopsychiatry, “Complete
remission (i.e., a return to full pre-morbid functioning) is probably not common in this
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disorder”, is quite clearly empirically invalid. To conclude, it is worth citing the entirety
of Harding and Zhasiner (1994) summarization of the longitudinal literature,
…all of these studies have come to the same conclusion. The longer investigators
followed an identified intact cohort (whether probands were in or out of
treatment), the more pronounced the picture of heterogeneity and improvement in
function. These studies have found that half to two thirds of patients significantly
improved or recovered, including some cohorts of very chronic cases…All of
these investigators of long-term studies were trained in the older, more pessimistic
conceptual models [i.e., Kraeplian degenerative brain disease model] and were
surprised by their own findings. Because the myths have been repeated so often,
they had become reified. The strong belief systems and resistance, encountered by
these investigators, were caused by many factors and were not easily altered by
one study. However, there is now a confluence of results (p. 141).
These longitudinal studies provide significant hope that schizophrenia is not degenerative
and that significant improvement and even recovery is quite possible, especially if
medication treatments are not relied on as the sole or primary intervention.
Simply because the biological and degenerative basis of schizophrenia is
empirically unfounded does not necessarily translate into the ineffectiveness of
medication treatments, though the poorer results of the richer, drug-reliant nations is not a
good starting point to claim clinical effectiveness. That is, it still may be possible to
successfully treat schizophrenia biologically even if it seems to be far more than just a
biological disease. Let us now turn to the empirical literature investigating the clinical
effectiveness of older and newer neuroleptic treatments.
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Section III: The Effectiveness and Safety of Neuroleptic Medications
The lack of evidence delineating the biological correlates of schizophrenia is not
what most sufferers and their families and friends are informed about schizophrenia
(Jackson, 2005). Breggin (1991) asserts that if patients were accurately informed of what
psychiatry does not know, use of neuroleptic medications as the primary treatment would
undoubtedly be questioned more deeply. Despite ever-ready proclamations of new
miracle biological therapies that will solve the schizophrenic puzzle (e.g., insulin coma,
lobotomy, electroshock, typical and atypical neuroleptics), none of these treatments have
ever proven to be very effective (Whitaker, 2002, 2005). This review will begin with the
older, typical neuroleptics.
Effectiveness of the Typical Neuroleptics
Epstein and colleagues (1962) investigated two groups of male, first-episode
schizophrenics admitted to nine California State Hospitals during 1956 (n = 673) and
1957 (n = 740). In 1956, 36% (n = 245) received neuroleptic treatment and 64% received
no medications. In 1957, 48% (n = 355) of the 740 patients received neuroleptic drug
treatment, compared to 52% (n = 385) who received none. The authors set out to
investigate whether or not drug treatments shortened hospital stays. Defying the myth
that neuroleptic drugs were responsible for ‘emptying the asylums’ (for a critique see
Jackson, 2005; Harding & Zahniser, 1994; Whitaker, 2002, 2005), Epstein et al. found
that schizophrenic patients treated with neuroleptics consistently – across nine different
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sites – had significantly longer hospital stays compared to patients who did not receive
medication treatment.
In 1967, Schooler and colleagues published one-year follow-up results for their
National Institute of Health project. The authors reported that the placebo group fared
significantly better in terms of clinical symptoms and reduced rates of hospitalization
compared to the three neuroleptic groups (chlorpromazine, fluphenazine, and
thioridazine). Post hoc analyses revealed that following discharge, psychotherapy but not
drug treatment, was associated with a higher level of social interaction and “a greater
likelihood of a wage earner’s job being commensurate with his training” (p. 991).
Further, rates of extrapyramidal side-effects were so severe in the chlorpromazine group
that 37% of the patients had to be placed on antiparkinsonian chemical agents. As will be
discussed below, these side-effects are largely permanent and at times fatal (Jackson,
2005). Ultimately, rather than staying close to the data and concluding that people with
schizophrenia do better with minimal neuroleptic exposure and/or psychotherapy-only,
Schooler et al. concluded, “…because we were unprepared to recommend placebo as
treatment of choice, we explored a number of possible variables that might have caused
this” (cited in Irwin, 2004a, p. 61). The variable with which they hoped to explain these
results is as follows: “when lack of improvement was observed in the patient [of the
placebo group]…it may be that the staff responded to the ‘deprived’ [off medication]
patient with some special quality of care” (p. 61). Needless to say, this conclusion is
clearly hyperbolic and has no supporting empirical evidence. Even if it was a valid
consideration it would actually only serve to advance the idea that human interactions are
quite helpful for people suffering with schizophrenia (e.g., milieu therapy, individual
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psychotherapy). Despite the explicit data, the author’s endorsement of neuroleptic
medications in their concluding remarks provide us perhaps with an early, though
instructive example, of the growing drug bias enveloping the field.
Prien and colleagues (1968) investigated relapse rates among chronic
schizophrenic patients over a six-month period when medications were withdrawn.
Relapse was defined as a return of positive symptoms, extreme hostility and excitement,
and/or threatening behaviors. Results were highly suggestive of a positive statistical
relationship between medication use and relapse. That is, relapse rates were positively
associated with neuroleptic medication dosage. Only 18% of the 65 patients receiving
less than 300 mg/day of chlorpromazine relapsed following medication withdrawal. In
contrast, of the 60 patients on moderate doses (300-500 mg/day) 47% relapsed; and, of
the 53 patients on high doses (greater than 500 mg/day) 58% relapsed. The relapse rate of
the low group was significantly different than the higher dose groups, although there was
no significant difference found between the moderate and high groups. Most relative to
this dissertation project is that of the 18 patients who were medication-free during the
entirety of the study, only one subject (6%) relapsed over the next six months (6%). In
sum, patients exposed to relatively less or no medications seemed to progress better in
terms of positive symptoms and interpersonally, whereas exposure to medications
precluded recovery and was associated with a greater potential for a return to psychotic
functioning.
In a subsequent study, Prien and colleagues (1971) replicated these results. Once
again, those patients who did not receive any medications throughout the study fared
significantly better. Only 2 of 30 patients who were on placebo at the start of the study
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relapsed during the next 24 weeks (7%), whereas the rate of relapse in the drug groups
were equal to the high rates found in the initial study. As a result, the authors concluded
once again, "Relapse was found to be significantly related to the dose of the tranquilizing
medication the patient was receiving before he was put on placebo - the higher the dose,
the greater the probability of relapse” (p. 22).
Another manner by which drug effectiveness can be determined is to compare
pre-drug era with drug era outcomes. Bockoven and Solomon (1975) compared relapse
rates of these two eras and found that 45 of the 100 randomly selected schizophrenic
patients treated at the Boston Psychopathic Hospital in 1947 (the pre-drug era) had not
relapsed in the five years following discharge. They also determined that 76% were
successfully living in the community at the end of that follow-up period. However, of the
100 randomly selected patients treated with medications in 1967 at a Boston community
health center, only 31 remained relapse-free for the next five years. The authors found
another troubling result from both a clinical and economic perspective: the medication
treated patients were much more "socially dependent" compared to the un-medicated
patients (i.e., in greater need of continuous state-supported day program treatment and
social welfare benefits; p. 801). As a result, the authors concluded, “One unexpected
finding of the comparison…is that these drugs might not be indispensable; in fact, they
might actually prolong the social dependency of some discharged patients” (p. 796).
Bockoven and Solomon’s results replicated larger sample studies in other cities
confirming the growing suspicion that neuroleptic medications have significant
limitations and dangers (Lehrman, 1960; Rachlin, Guritz, Lurie, & Rachlin, 1956).
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In their review of 13 neuroleptic treatment studies conducted between 1959 and
1974, Gardos and Cole (1977) found a significant difference between the relative
psychological health of relapsers depending on prior treatment with placebo or
neuroleptics. They reported that people who relapse following drug exposure “are sicker
than placebo relapsers” (p. 34). Due to the ‘medicate-first’ trend that had already
entrenched itself within the field they wrote, “The suggestion that as many as half of
schizophrenic patients might not be worse off their…medication…will surely meet with
some raised eyebrows” (p. 34). Nonetheless, sticking close to their data they suggested,
“The major principle we wish to stress is that every chronic schizophrenia outpatient
maintained on an antipsychotic medication should have the benefit of an adequate trial
without drugs” (p.35; my emphasis). The authors admonished psychiatrists to rethink
current medication treatment strategies based not only on their specific relapse results,
but also as a result of the permanent side-effects induced by these drugs.
In the late 1970s, investigators helped explain existing evidence indicating that
neuroleptic drugs cause a greater number of relapses, more regressed relapses, as well as
poorer symptomatic and social outcome, by identifying the specific biological changes
induced in the brain by neuroleptic medications. Chouinard and colleagues (Chouinard,
Jones, & Annable 1978; Chouinard & Jones, 1980; Muller & Seeman, 1978) found that
because neuroleptic drugs greatly decrease dopamine activity the brain compensates by
becoming ‘supersensitive’ to dopamine by initiating a proliferation of dopamine
receptors. As a result, when a patient stops taking dopamine blockers (i.e., neuroleptics)
the brain is standing by with a far greater number of dopamine receptors to take in an
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unusually high amount of dopamine and is therefore more biologically prone to
psychosis. Chouinard (1978) remarks in this regard,
Neuroleptics can produce a dopamine supersensitivity that leads to both
dyskinetic (i.e., parkinsonian symptoms) and psychotic symptoms. An implication
is that the tendency toward psychotic relapse in a patient who has developed such
a supersensitivity is determined by more than just the normal course of the
illness...[and] the need for continued neuroleptic treatment may itself be druginduced (p. 1410; my emphasis).
Although psychiatrists often interpret the resurgence of psychotic symptoms as a return
of the underlying schizophrenic brain disease and justification for lifelong neuroleptic
management, this research conducted almost 40 years ago definitively showed that
relapse is more related to drug-induced psychosis and not to any pre-existing
schizophrenic deficit.
Recently, Moncrieff (2006) summarized the literature exploring the relationship
between drug exposure and ‘supersensitivity psychosis’ and confirmed these original
studies of the 1970s. Moncrieff’s research, unlike the earlier studies, was able to include
the newer generation of atypical neuroleptics in his review and found that they too are
implicated in withdrawal-related psychosis. He writes, “It appears that the psychosis
[evident upon relapse] may be a feature of drug withdrawal rather than the emergence of
the underlying illness…” (p. 1). In other words, not only have neuroleptics been shown to
be ineffective but also harmful above and beyond the well-known side-effects to be
discussed below. These authors and others have also concluded that these supersensitivity
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effects may be irreversible similar to tardive dyskinesia 4 and other diseases (e.g.,
diabetes) produced by neuroleptic medications.
Needless to say, the NIMH of the 1970s was startled by these findings that
indicated the ineffectiveness and dangerousness of neuroleptic drugs. As a result, the
NIMH was compelled to revisit whether or not schizophrenia could be successfully
treated without drugs (Whitaker, 2002). Three NIMH-funded studies were conducted to
explore this idea, all of which concluded that newly admitted schizophrenics fared better
when treated without drugs.
Carpenter, McGlashan and Strauss (1977) conducted the first of three NIMH
studies. In this investigation, 49 schizophrenia patients were placed in an experimental
hospital program that provided them with individual and group psychodynamic
psychotherapy. These patients were compared to 73 schizophrenia patients receiving
status quo drug treatments. Only 35% of the non-medicated patients relapsed within a
year after discharge, compared to 45% of those treated with medication. The medicated
patients also experienced more depression, blunted emotions, and retarded movements.
An obvious but no less important observation was that the non-drug treated patients did
not have to endure the many different marked physiological and emotional side-effects
associated with neuroleptic use.
In a study of young male schizophrenics, Rappaport and colleagues (1978) found
that patients treated without mediations while in the hospital and did not use medications
during the three year follow-up period fared significantly better than 1) patients treated
4

Tardive dyskinesia is an irreversible physiological disease that results in involuntary and irregular muscle
movements, usually, but not limited to, the facial region. Tardive dyskinesia and a number of other
extrapyramidal side-effects associated with neuroleptic exposure will be discussed in greater detail below.
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with medications while in and outside the hospital; 2) patients treated with medications
while in but not outside the hospital; as well as 3) patients not treated with medications in
the hospital but with medications during the follow-up period. That is, simply stated, the
least possible exposure to medications the better, particularly in regard to symptoms, rehospitalizations, need for continued treatment and communal functioning. The authors
concluded, “Routine and continuous use of [neuroleptics] may be contraindicated…” (p.
107). Further, the authors make a statement one would be hard-pressed to find in the
current mainstream biopsychiatric literature, “The findings underlie the need for further
study of how to utilize antipsychotic medication more selectively in the treatment of
schizophrenia” (p. 100).
In the last of the three NIMH studies, Matthews and colleagues (1979) reported
that patients treated without neuroleptics in a non-professionally staffed milieu setting
fared better than patients treated with medically trained doctors administering
neuroleptics. By six weeks, the two groups fared equally well in regard to
psychopathology, refuting the claim that neuroleptics are far superior for short-term
decreases in acute positive symptoms. Over the two-year follow-up period, the unmedicated patients had a healthier level of social functioning, reported less subjective
distress, and were incurring less treatment costs compared to the drug group. These
results have been replicated by U.S. and international researchers (Cullberg, 1991; Karon
& Vandenbos, 1981; Lehtinen, Aaltonen, Koffert, Rakkolainen, & Syvalahti, 2000;
Mosher, Vallone, and Menn, 1979). Carpenter et al. (1977) succinctly sums the NIMHfunded research of the 1970s,
There is no question that, once patients are placed on medication, they are less
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vulnerable to relapse if maintained on neuroleptics. But what if these patients had
never been treated with drugs to begin with?... We raise the possibility that
antipsychotic medication may make some schizophrenic patients more vulnerable
to future relapse than would be the case in the natural course of the illness (p. 19).
Despite the clear-cut conclusions favoring the non-drug treatments of all three NIMH and
replication studies, the NIMH has decidedly moved away from this type of research.
These studies had virtually no impact on the dominant position of drugs in the treatment
of schizophrenia – yesterday or today (Breggin, 1991; Jackson, 2005). These studies
became even more irrelevant in the minds of mainstream biopsychiatric researchers and
clinicians following the development of the newer atypical neuroleptics (in the 1990s)
which biopsychiatry currently deems superior to the older typical neuroleptics. However,
as will be seen below, the superiority of atypicals over typicals is a faulty assumption that
has further contributed to the over-reliance of neuroleptics as the frontline treatment for
schizophrenia sufferers. Prior to direct empirical comparison of the older and newer
drugs, in the service of an honest appraisal of drug treatments for schizophrenia, further
review of studies that include both older and newer neuroleptics is in order.
Effectiveness Research Including Typical and Atypical Neuroleptics
If typical and atypical neuroleptics truly have specific ‘antipsychotic’ effects then
they should show superior effects compared to simple sedatives (e.g., benzodiazepines).
Yet, all reviews of the relatively scant ‘neuroleptic versus sedative’ literature found no
differences between the two treatments (Carpenter, 1999; Keck, 1989; Wolkowitz, 1991).
Whitaker (2002) ironically summed the evidence, “Forty years after neuroleptics were
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introduced, and still there was no convincing proof that the [neuroleptic] drugs were any
better at knocking down psychosis than old-fashioned opium powder” (p. 200). In
response to these unsettling results, Turns (1990) self-deprecatingly asks, “Has our
clinical judgment about the efficacy of antipsychotics been a fixed, encapsulated,
delusional perception…Are we back to square one in antipsychotic
psychopharmacology?” (cited in Whitaker, 2002, p. 200).
Healy and colleagues (2005) took advantage of an idiosyncratic demographic
situation in North Wales to study the effectiveness of psychiatric medications. In the
region under investigation the population has been stable for at least a 100-year period in
terms of number of people, age, ethnic mix and rurality. The authors found that there has
been a three-fold increase in the rate of detention into psychiatric services and a 15-fold
increase in the rate of hospitalizations since the introduction of medications. Speaking
directly to medication effectiveness, the periods of healthy functioning for psychotic
disorders such as bipolar disorders have actually become shorter, indicating that people
are sicker more rather than less of the time. Overall, mentally ill patients spend a greater
amount of time in a hospital bed today then they did 50 or 100 years ago. That is,
treatments are becoming increasingly ineffective, even relative to Victorian times.
Not unlike the results presented earlier (Chouinard et al., 1978; Chouinard &
Jones, 1980; Matthews et al., 1978; Mosher et al., 1979; Muller & Seeman, 1978),
Whitaker (2005) has pointed out that medications are partially responsible for evergreater cases of chronic schizophrenia. He reported multi-site MRI evidence that have
shown a connection between neuroleptic drug usage and enlargement of the basal ganglia
which has been linked to greater severity of both positive and negative symptoms (e.g.,
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Gur et al., 1998). Whitaker (2005) concluded, “In other words, [research has] found that
over the long term, the drugs cause changes in the brain associated with a worsening of
the very symptoms the drugs are supposed to alleviate” (p. 8).
Right up until the advent of the newer and more expensive atypical neuroleptics
the drug industry and mainstream biopsychiatry actively promoted the effectiveness and
safety of the original typical neuroleptics. Upon the advent of the atypicals, one finds
greater discussion of the danger and marginal effectiveness of the typical neuroleptics
once deemed ‘miracle cures’. Some believe that this honesty is better explained by the
need for the drug-industry to promote and sell its more expensive atypicals now that the
older drugs have lost their patents and thus profitability (Breggin, 1991; Whitaker, 2002).
Within psychiatry and psychology, it is a widespread belief that the atypicals are
clinically superior and safer than their predecessors. As will be shown, this belief is
predicated upon information stemming from randomized controlled trials (RCT) mainly
undertaken by drug companies during the FDA approval process. However, there are
significant methodological flaws inherent in these trials, as well as a good deal of nondrug company research refuting the superior effectiveness and safety of the atypicals. To
this topic I now turn.
Atypical Neuroleptics versus Typical Neuroleptics
There is little sound scientific evidence indicating the superior safety and
effectiveness of the newer, atypical neuroleptic medications (Stip, 2002). Why then do
the newer atypicals hold a 90% market share in the United States? The potential answer
to this question may be that “physicians have come to rely increasingly upon information
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from published sources (e.g., clinical drug trials) rather than from direct observation” or
non-drug industry supported research (Jackson, 2005, p. 7) As the main data source for
psychiatrists, it is imperative to understand the contemporary FDA drug trial research
design (i.e., the Randomized Controlled Trials) employed by pharmaceutical companies
that brings psychiatric drugs to the marketplace and justifies their widespread use for the
treatment of schizophrenia.
How a Psychiatric Drug Comes to the Marketplace
In 1962 the U.S. Congress empowered the FDA with the responsibility of
assessing the therapeutic efficacy and safety of medications for inclusion in the
marketplace. Because psychiatrists and other medical professionals rely almost entirely
on the data generated in these drug trials for informing treatment, it is essential to
understand the methodology of this process. Further, it is important to keep in mind that
the RCT is also the preferred design for the subsequent, post-FDA approval process
studies also generally sponsored by pharmaceutical companies. Thus, the following
critique is generalizable to the vast majority of pre- and post-approval drug efficacy
studies (Hegarty, Baldessarini, Tohen, Waternaux, & Oepen, 1994; Jackson, 2005;
Thornley & Adams, 1998).
The FDA drug development process is divided into four phases. Phase I, or the
‘Pre-Clinical Investigations’, involve the study of a drug’s effects on animals, cell
cultures, and tissue samples. This phase aids in the determination of metabolic pathways,
possible mechanisms of action, and toxicity.
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In Phases II-IV, the ‘Pre-Marketing Clinical Investigations’, human subjects are
brought into the process. Phase II typically includes 100 healthy volunteers, with the
intention of determining any adverse effects and general drug metabolism processes not
detected in non-human species. This phase is essential for the development of a safe dose
range without significant negative side effects.
Phase III includes between 100-300 individuals suffering from the illness the drug
is meant to treat. The goal of Phase III is to fine tune dose range and nascent ideas
regarding the drug’s efficacy for use with actual patients.
Phase IV studies are the last investigations required before receiving FDA
approval. These studies are randomized, controlled, double-blinded trials consisting of
approximately 1000 participants and commonly known as Randomized Controlled Trials,
or RCT’s. RCT’s are short-term (4-8 weeks) and involve the testing of the proposed drug
against other biological treatments and placebo (usually sugar pills). Upon completion of
Phase IV, the pharmaceutical company files a ‘New Drug Application’ with the FDA
outlining the results of the four phases.
The FDA looks for efficacy in at least two similar and well-monitored Phase IV
trials. Efficacy is defined as “a statistically significant, therapeutic effect in the absence
of unacceptable toxicities” (Hall, 2003, cited in Jackson, 2005, p. 9). Effect in this case is
defined by comparing untreated (i.e., placebo) with drug-treated subjects, therefore there
is no requirement that the proposed drug exhibit statistical superiority to other treatments
such as psychotherapy. The FDA’s standard for psychiatric drug approval is “far more
ambiguous than may be commonly assumed” (Jackson, 2005, p. 9). This ambiguity is not
speculation, rather, it is a fact acknowledged by the FDA,
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The evidence adduced in the sponsor’s short term studies, although it
unquestionably provides compelling proof in principle of (the drug’s) acute
action, it does not provide a useful quantitative estimate of how effective the drug
actually will be in the population for whom it is likely to be prescribed upon
marketing (Leber, 1996, cited in Jackson, 2005, p. 10).
The RCT method and design that provides “proof in principal” but not a “useful
quantitative estimate” may be seriously flawed. Considering that these drug trials provide
the evidence that guides schizophrenia treatment a more nuanced breakdown of the RCT
is in order to clearly ascertain what we know and do not know about the safety and
efficacy of antipsychotic medications.
The RCT: A Scientifically and Clinically Flawed Approach
Published overviews regarding pharmaceutical company sponsored drug trials
point out profound deficiencies in published and unpublished FDA research methods and
designs (Antonuccio, Danton, & McClanahan, 2003; Breggin, 1991; Moncrieff, 2001;
Safer, 2002; Whitaker, 2002). Again, it is essential to keep in mind that the RCT is the
preferred design for subsequent, non-FDA studies as well. Thus the following critique is
generalizable to the vast majority of drug efficacy studies used by psychiatrists when
selecting treatments (Jackson, 2005; Thornley & Adams, 1998). Jackson (2005) provides
the most recent integration of these critiques of the RCT and I will summarize her
findings by highlighting the methodological flaws most relevant to the neuroleptic drugs
currently used for the treatment of schizophrenia.
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Flaw #1: Ecological Validity and Selection Bias. A main strategy in a drug study
is to narrow the subjects as much as possible. Logically, this makes sense since the aim of
a drug study is to determine efficacy of a certain drug with a certain illness. However, in
the real world of clinical practice there is rarely such a thing as a ‘pure schizophrenic’.
Yet, this is what the RCT design attempts to achieve. Common exclusions in an RCT are
any or all of the following: age younger than 18 or older than 65; co-morbid physical or
mental illness; pregnancy; severe distress (e.g., suicidal thoughts); inpatient status; and
poor response to previous treatment. Rather than including these all-too-common
variables as potentially informative covariates, they are generally excluded. The comorbidity exclusion is particularly problematic because contemporary research indicates
that multiple Axis I problems are often intertwined with multiple Axis II personality
processes greater than 50% of the time (Westen, Novotny, & Thompson-Brenner, 2004).
Flaw #2: Non-equivalent Dosing. In Phase IV of the FDA process, efficacy and
safety are the target concerns. In these studies the newer atypical neuroleptics are
compared to older typical neuroleptics. Equivalent dosing is defined as the administration
of comparable doses of each drug, based on the well-defined chemical standards
(Bezchlibynk-Butler & Jeffries, 2002). Non-equivalent dosing is the use of “super doses”
(Jackson, 2005, p. 28) for one or the other medication in the trial. Since Phase IV
concerns a patient simply staying on the drug for both a measure of efficacy and safety
(i.e., no intolerable side effects resulting in discontinuation from drug exposure), dosing
is an integral aspect of outcome. Obviously, it is scientifically and clinically unwise to
use non-equivalent dosing since this will potentially lead to intolerable and/or dangerous
side effects for a particular study group, and therefore disallow actual comparison of the
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drugs themselves. Yet, this is the common practice for manufacturers seeking to gain
approval for a new product. This strategy makes it more likely for researchers to
conclude that the newer (i.e., more expensive product with a new patent) drug is safer and
more effective. Of course, whatever symptom ratings scales are used will also reflect the
newer drug’s superiority, because patients being overdosed on the older drug are in
tremendous distress, both mentally and physiologically. Further, the hyper-sedative and
other deleterious side effects of overdosing will artificially widen the gap between the
groups in regard to negative symptoms (e.g., apathy, social isolation, flat affect). This is
the origin of the regularly reported belief that compared to older typical agents the
atypical antipsychotics are more effective for the treatment of negative symptoms.
Phase IV of the atypical neuroleptic olanzapine approval process provides an
illustrative example of non-equivalent dosing. In this study, olanzapine was compared to
the typical neuroleptic haloperidol in the hope that it would provide compelling empirical
proof to psychiatrists and other health care professionals that this new drug is safer and
more effective and therefore should be turned to as a frontline treatment for
schizophrenia. Table 2 illustrates the non-equivalent dosing strategy (Jackson, 2005, p.
29). A comparable dose of haloperidol to olanzapine is 2 mg to 10 mg, respectively.
Thus, in the high dose groups, haloperidol subjects received 4-6 times the olanzapine
dose; in the medium groups, haloperidol subjects received 7-8 times the olanzapine dose;
and in the low dose groups, haloperidol subjects received 8-20 times the olanzapine dose.
Subsequent studies using either equivalent dosing (Rosenheck et al., 2004) or naturalistic
design (Lieberman et al., 2005) have not found any of the atypicals to be superior in most
respects when compared to the older medications.
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Flaw #3: Concomitant Medications. For patients with co-morbid ailments (e.g.,
diabetes), adjunctive medications are often being ingested during a drug trial. Of course,
most if not all drugs cross the blood brain barrier and thus actively impact thinking,
affect, and behavior (Breggin, 1991; Jackson, 2005). Although these potentially
important covariates should undoubtedly be analyzed, they are ignored in RCT drug
trials. Oddly, even when investigators prescribe a drug to ameliorate side effects of the
study medication (e.g., drooling), this is not disclosed publicly nor is it analyzed
empirically.
Flaw #4: Placebo Washout. Placebo washout is perhaps the most important factor
leading to distorted information passed on to psychiatrists. Similar to non-equivalent
dosing (Flaw #2), this practice is dangerous to the physiological and emotional wellbeing of research participants. ‘Placebo washout’ is the 7-10 day period during which all
participants abruptly discontinue previous medications immediately preceding the
initiation of an RCT study. The intent is to ‘washout’ the brain of any chemicals so that
prior drug use does not influence the study. The word ‘placebo’ is used because all
participants are given an inert substance during this period so that subjects are not aware
they have discontinued their medications. Upon initiation of the study the placebo group
will of course continue to receive the inert pill or an older typical neuroleptic, while the
experimental group will receive the drug under investigation. There are a variety of
critical problems with this approach that result in significantly biased results that favor
the experimental drug.
First, any patients who exhibit a positive response during the washout phase are
removed from the study. As Jackson (2005) writes,
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…it is impossible to discount the presence of the same placebo effect…in the
subjects who go on to receive the active drug. As the placebo effect is necessarily
a part of all healing rituals, it is illogically inconsistent to remove some subjects
from a study, simply because they manifest this response too quickly (p. 31).
Data provided by Faries and colleagues (2001) show that these positive responders
continue to do well as the trial continues without active drugs. Consequently, removing
these patients artificially inflates the differences between the experimental and control
groups. Second, and more importantly, it is common that people experiencing abrupt,
‘cold turkey’ discontinuation will experience substantial physiological and emotional
fallout (Moncrieff, 2006). What is particularly strange about this practice is that abrupt
withdrawal is widely documented within the mainstream psychiatric literature to be very
dangerous (Addonizio, Susman, & Roth, 1987; Kornhuber & Weller, 1994). The most
efficient, safest, and quickest way to moderate acute withdrawal symptoms is to provide a
chemical intervention. Thus, most subjects in the placebo group experiencing acute
withdrawal symptoms are at a significant disadvantage, since their bodies continue to
adapt slowly to the sudden chemical changes. In contrast, the acute withdrawal symptoms
of those in the experimental drug group are buffered more quickly with the
administration of an active drug compound. This procedure translates into drug trials that
are not measuring the effects of drugs or placebos on an underlying psychosis, but rather
the treatment of acute withdrawal symptoms. Beyond this, it is empirically well-founded
that the body cannot expunge the chemical properties of psychiatric agents within 7-10
days (Breggin & Cohen, 1999; Hubbard, Ganes, & Midha, 1987). Rather, the withdrawal
process takes weeks or months, and if attempted too quickly has permanent consequences
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on brain tissue and neurologic pathways (Viguera, Baldessarini, Hegarty, van Kammen,
& Tohen, 1997). These factors inculcate a unique bias into the antipsychotic drug trial
literature and clinical practice.
Flaw #5: Last Observation Carried Forward (LOCF) Analysis. LOCF is a
statistical technique for reporting results of subjects who drop-out of a trial in which the
researchers use the last recorded assessment for final outcome no matter the point at
which they drop out (post-placebo washout). The assumption, of course, is that there
would be no change if those participants had remained in the study. This often puts the
placebo group at a profound disadvantage since many patients in this group drop out at
their most distressed point of medication withdrawal immediately following the end of
the placebo washout period. Of course, this practice artificially inflates the results of the
experimental drug group.
Flaw #6: Unblinding. The double-blinded study design is intended to prevent
patients, researchers, and clinicians (and anyone else connected to the study) from
knowing group assignments. Due to the overt side effects of psychiatric medications,
which are easily recognized by clinicians and researchers (and likely by patients),
‘unblinding’ is common in drug trials and thus results may be strongly influenced by
treatment expectations.
Flaw #7: Omission of Data and Methodological Changes. In their review of 10
drugs approved by the FDA between 1987 and 1997, Khan and colleagues (2000, 2001)
found that drug companies omitted important and relevant data. The most serious
omissions were the unreported data tracking suicide attempts and completed suicides for
two antidepressants and two atypical antipsychotics. Additionally, during the olanzapine
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approval process researchers changed the study from a 6-week study to a 4-week study
due to too many subjects in the olanzapine group dropping out as a result of intolerable
side effects (Jackson, 2005). The 6-week data was omitted from the final reports and only
discovered by a request taking advantage of the congressional Freedom of Information
Act. Recalculation of the 6-week data revealed results that are far less positive for
olanzapine. Of course, omitted data and methodological changes make it difficult for
subsequent researchers and clinicians to study and use the drug most effectively, safely,
or not at all. The most recent (January 2007), but not isolated example of data omission,
was seen in Eli Lilly’s recent $1.2 billion class-action settlement resulting from their
failure to report results regarding the association between olanzapine, diabetes and
morbid weight gain.
Flaw #8: Redundant Publications, Suppression of Negative Results, and GhostWriting. Recently, pharmaceutical company Eli Lilly has been found guilty of repackaging the same trial data in a series of overlapping papers in regard to the olanzapine
approval process. Similarly, Glaxo Smith Kline recently re-packaged data in an attempt
to exhibit the superiority of its product over a competitor’s drug. Besides this being a
medical ethics violation, redundant publishing changes the findings of meta-analyses and
thus evidenced-based medicine as we know it.
In regard to negative results, there are two important distortions that impact the
objectivity and validity of the drug trial literature. First, litigation has shown that drug
companies have hidden negative results not only from the public, but from the FDA as
well (Jackson, 2005). Second, many researchers who have conducted FDA trials are
silenced by non-disclosure agreements, thus greatly tying their hands in regard to
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reporting or whistle-blowing about dangerous medications. Antonuccio, Danton, and
McClanahan (2003), Breggin (1991), and Ross and Pam (1995) all provide extensive
documentation of these ethical violations. Third, ‘ghost writing’ is when an academic is
paid to place his or her name on a paper or conference presentation to lend it authority.
According to the deputy editor of the Journal of the American Medical Association, “This
practice is well-known, scandalous, and outrageous. It is a perfect illustration of
deceptive authorship practices for commercial reasons” (Larkin, 1999, cited in Jackson,
2005, p. 39).
The substantial flaws of controlled studies have recently been quantified in an
extensive review of neuroleptic research, the results of which further erode confidence in
the efficacy literature. In 1998, British researchers analyzed 2000 controlled efficacy
trials conducted over the past 50 years (Thornley & Adams, 1998). The authors rated
research methodologies according to the quality of randomization, blinding procedures,
and the handling of patient attrition. Studies included consisted of trials of older and
newer neuroleptics.
In regard to overall quality of reporting, only 4% of the trials described how
patients were assigned to experimental versus control groups; only 22% of the studies
described blinding procedures; and only 42% of the trials described treatment
withdrawals. The latter is highly significant because it speaks directly to the feasibility of
treatment compliance, side-effects of the drugs, and physiological and psychological
fallout resulting from placebo washout. Astoundingly, only 1% of the studies were
considered of good quality.

52

Significantly, the duration of each trial was very brief. Whereas only 19% of the
trials lasted for more than six months, more than half (54%) lasted six weeks or less.
Considering the complex nature of schizophrenia and the amount of time it generally
takes for people to show improvement (e.g., WHO studies), short trials are extremely
non-representative of real-world treatment and clinical course. Furthermore, for a drug to
be approved by the FDA and to be considered useful in general, it has to be shown to be
not only efficacious, but safe for human consumption. Most central to safety, the very
brief length of these studies makes it nearly impossible for drug trial researchers and the
FDA to fully assess the inevitable short-term, but specifically long-term safety of
neuroleptic drugs. This is highly problematic because it is common psychiatric practice to
use neuroleptics as ‘maintenance medications’. That is, based on the general
biopsychiatric belief that schizophrenia is a degenerative, incurable, chronic brain
disease, neuroleptics are used for many years. In this sense, the brief drug trials do not
approach a realistic assessment of long-term physiological and emotional side-effects.
In sum, Thornley and Adams (1998) conclude, “The consistently poor quality of
reporting is likely to have resulted in an overoptimistic estimation of the effects of
[neuroleptic] treatment” (p. 1184). In response, Jackson (2005) writes of the accumulated
neuroleptic effectiveness evidence,
When, on rare occasion, the results of long-term…studies have appeared, the
research has consistently supported the view that antipsychotics do more to
impede, rather than facilitate, the recovery and longevity of many patients...
Moreover, the low quality of the clinical trials have pervaded the psychiatric
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literature has contributed to a body of evidence…whose validity and clinical
relevance remain contestable (p. 191).
Even with the pro-drug biases inherent in the FDA and non-FDA trial methodologies, the
performance of new (and old) neuroleptics has been generally unremarkable (Stip, 2002).
Despite the serious methodological flaws of the typical RCT, I will discuss the most
recent meta-analyses and other studies to more clearly illuminate the strengths and
weaknesses of the newer, atypical neuroleptics.
Chakos and colleagues (2001) investigated the comparative utility of the atypicals
in a twelve-study meta-analysis of treatment-refractory schizophrenia and concluded,
“Efficacy data for other second-generation antipsychotics in the treatment of patients with
refractory schizophrenia were inconclusive” (p. 518). Considering that studies included in
the meta-analysis suffer from the pro-atypical neuroleptic biases just presented
(‘superdoses’ of older drugs, placebo washout, LOCF, etc.) it is particularly informative
that the results still did not favor the newer drugs. Furthermore, Chakos et al. (2001)
identified a positive association between trial duration and drug efficacy, with longer
study periods (i.e., a scenario more comparable to day-to-day psychiatric practice)
eroding the few observed differences found between the older and newer drugs. All in all
this meta-analysis refutes the superiority of the newer medications.
Geddes and colleagues (2000) report results of a far larger meta-analysis (n =
12,649) exploring the comparative value of the older and newer neuroleptics. Their
results run contrary to the mainstream perception that atypicals are more efficacious and
easier to tolerate in regard to side-effects. The authors conclude,
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There is no clear evidence that atypical antipsychotics are more effective or are
better tolerated than conventional antipsychotics. Conventional antipsychotics
should usually be used in the initial treatment of an episode of schizophrenia
unless the patient has previously not responded to these drugs or has unacceptable
extrapyramidal side effects (p. 1371).
These meta-analytic results have been replicated in prospective studies involving
relatively chronic schizophrenic patients (Rosenheck et al., 2004), as well as patients
earlier in their course of illness (Lieberman et al., 2003).
In a prospective, 12-month, multi-site drug trial comparing the atypical
olanzapine with the typical haloperidol, Rosenheck and colleagues (2004) found no
advantages for the newer drug in regard to treatment compliance (i.e., tolerability of sideeffects), psychotic symptoms, the development of extrapyramidal symptoms,
improvement in interpersonal relationships, employment earnings, or overall quality of
life. They did find that olanzapine reduced incidence of akathisia,5 but that these lower
risks were offset by the significant weight gain, the development of diabetes, and
treatment costs associated with olanzapine.
Lieberman et al. (2003) conducted a multi-site trial of olanzapine versus
haloperidol in the treatment of recent onset schizophrenia. Despite significant
methodological confounds favoring the atypical olanzapine, the authors still failed to
detect any significant differences between the two medications. One outcome that was
surprising was the high incidence of parkinsonism and akathisa among the olanzapine
5

Akathisia is a feeling of inner restlessness that results in a constant urge to move. While one cannot keep
still when afflicted with akathisia, the movements are voluntary. This is distinct from the involuntary
movements associated with tardive dyskinesia. These and other side-effects associated with exposure to
neuroleptics will discussed in greater detail below.
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participants. This was an unexpected finding because the newer drugs are supposed to be
less dangerous in regard to extrapyramidal side effects.
Perhaps in response to the many flaws of the RCT efficacy trials, the National
Institutes of Mental Health (NIMH) is currently funding the largest-to-date, multi-site
drug study to determine the effectiveness of atypical versus typical neuroleptics in
naturalistic settings (e.g., community clinics). The naturalistic, effectiveness design will
allow for longer periods of observation, less exclusion criteria, and will be far more
generalizable to day-to-day practice compared to the RCT efficacy trials (for a discussion
of the difference between effectiveness versus efficacy in treatment outcome research see
Hilsenroth, Ackerman, Blagys, Baity, & Mooney, 2003). Also, the un-ignorable side
effects observed by real-world practitioners belies the supposed safety of these drugs as
reported in very brief drug trials and has further motivated a more ecologically valid,
effectiveness trial. This ongoing study is known as the Clinical Antipsychotics Trial of
Intervention Effectiveness (CATIE).
CATIE: The Largest Naturalistic Study of Neuroleptics to Date
Lieberman and colleagues (2005) report the results of Phase I of CATIE that
examined the comparative effectiveness of atypical versus typical antipsychotic
medications. Their findings further refute the widely asserted proclamations that atypicals
are actually more effective and have fewer side effects compared to older drugs.
Lieberman et al. (2005) report no significant differences in the effectiveness of
typical versus atypical drugs (n = 1432). As a measure of outcome they used early
discontinuation due to intolerable side effects (the maximum length of Phase I was set at
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18 months). It is important to not overlook the assumptions inherent in using early
discontinuation as an outcome measure. Inherently, this assumes that simply staying on a
medication indicates positive outcome, rather than measuring subjective or other
clinically-observed change variables. Nonetheless, early discontinuation due to side
effects does illuminate, at least partially, the feasibility of older and newer neuroleptics.
The authors report mean early discontinuation rates across all drugs was an astoundingly
high 74%. That is, only one in four participants was able to tolerate the drug for the
entirety of the study period. The older drug, perphenazine, was not outperformed by any
of the newer, far more expensive atypicals used with the greatest frequency in current
clinical practice. The authors acknowledge that there is nothing unique about this finding
because it is actually “consistent with…previously observed” outcomes found in smaller
trials (pp. 1217-8). They conclude that the use of typical and atypical drugs exhibit
“substantial limitations” (p. 1218). Yet, the authors do not offer any alternative other than
to inform “patients, families, and policymakers [to] evaluate the trade-offs between
efficacy and side-effects” (p. 1222). This recommendation is made despite the admission
that, “The results of [this and other] studies of the effects of treatment on cognitive
impairments and mood symptoms have been inconclusive…and incompletely explored”
(Lieberman, 2005, p 1210).
The authors of this paper fail to recommend that alternative approaches should be
considered, despite available evidence indicating the safety and effectiveness of
psychotherapeutic interventions (discussed below). Further, the fact that Lieberman et al.
(2005) make conclusive remarks regarding the effectiveness of drugs based on
approximately 25% of the subjects who managed to not drop-out speaks to their seeming
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unwillingness to consider the overall danger and ineffectiveness of these treatments.
After all, if three of four people stopped taking penicillin due to its intolerable side effects
during WWII would the U.S. government have considered this an effective treatment for
battle wounds, especially if viable alternatives were available? Such a scenario would be
highly unlikely. Yet, when it comes to the neuroleptic treatment of schizophrenia, this
level of ineffectiveness and physiological and emotional intolerableness is not merely
acceptable, but deemed preferable.
In conclusion, Gabbard and Freedman (2006) refer to Harvard social psychiatrist
Leon Eisenberg’s cautionary comments on biopsychiatry’s neurobiological reductionism
and concordant mandate for a medication-only approach in our field. They note,
These directions recall Leon Eisenberg’s prediction that when the
ultimate neurobiological treatment for schizophrenia is someday devised
and everyone is marveling over the results on the computer monitor, there
may be only one psychiatrist left who will remember to ask the patient,
‘How do you feel’ (p. 183).
Review of the most common side-effects of neruoleptic treatment is in order to further
assess the effectiveness and safety of neuroleptic medications.
Side-Effects of Neuroleptic Medications
The neuroleptic toxicity literature is rapidly growing as the dangerous short- and
long-term side-effects of these chemical agents become increasingly clear to
psychiatrists, consumers, their loved ones, as well as concerned patients’ rights
advocates. While this review is not intended to be exhaustive, it will provide an
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illustrative sampling of the most prevalent hazards associated with neuroleptic use. The
interested reader would be well-served to read Jackson (2005) as well as Owens (1999)
for more detailed accounts.
The most commonly recognized side-effects of neuroleptic use are known as
‘extrapyramidal side-effects’ (EPS). EPS are the various movement disorders suffered as
a result of ingesting neuroleptic dopamine antagonists. The best known EPS is tardive
dyskinesia (TD) which results in involuntary, irregular muscle movements usually, but
not limited to the facial region. For example, the patient may have facial tics, roll the
tongue, lick the lips, and/or have trembling hands. Although TD might be managed or
minimized by reducing the medication dosage or by changing type of medication, the
symptoms may persist for long periods and often permanently, even after neuroleptics are
decreased or even discontinued (Breggin, 1991, 1997; Jackson, 2005).
Some forms of TD involve damage to the respiratory system which results in
hyperventilation, abnormal vocalizations such as grunting, and violent chest contractions
that can result in rib fractures (Hayashi, Nishikawa, Koga, Uchida & Yamawaki, 1996;
Leung, Chung, Kam, & Wat, 2000). TD has regularly been empirically associated with an
exacerbation of crippling negative symptoms such as social isolation and anhedonia
(Waddington & Youssef, 1986), as well as positive symptoms (Miller et al., 2005).
Other common EPS include acute dystonia which is an abnormal drug-induced
state of either excessive or inadequate muscle tone. There are many forms of dystonia
disorders which cause involuntary movements and prolonged muscle contraction
resulting in twisting body motions, tremor, and abnormal posture, all of which are very
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painful for the sufferer. These movements may involve the entire body or only an isolated
area (Jackson, 2005).
Many patients develop symptoms that mimic those of people suffering from
Parkinson´s disease (Breggin, 1991). The symptoms include tremors, rigidity, temporary
paralysis, reduced facial expression, shuffling gait and extreme slowness of movement.
These symptoms usually appears in the first few days and weeks of neuroleptic
medication administration.
Akathisia is a serious condition associated with the use of neuroleptic medications
and characterized by an internal sense of extreme agitation and motor restlessness
(Jackson, 2005). Patients often describe their experience as being defined by an absolute
inability to resist the urge to move. The most widely observed form of akathisia involves
pacing and an inability to sit still. This side effect is often very distressing to the patient
and reduces his or her ability to perform every day tasks. This bizarre consequence of
neuroleptics also invites odd stares and exacerbates an already significant level of social
alienation.
A potentially fatal side-effect of neuroleptic treatment is known as neuroleptic
malignant syndrome (NMS; Jackson, 2005). NMS includes diffuse muscle rigidity,
tremor, high fever, labile blood pressure, cognitive dysfunction, and autonomic
disturbances. This condition can be sudden and often occurs early in the course of
treatment. However, it has also been documented to occur after months and years of
neuroleptic medication use.
In a recent review of the EPS literature, Glazer (2000) summed evidence from a
cohort of 362 patients. Glazer found a positive relationship between cumulative duration
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of neuroleptic treatment and EPS, thereby replicating previous reviews (e.g., Glazer,
1992). It is widely assumed that EPS develops only after years of exposure to
neuroleptics. However, Jeste and colleagues (1999) found that older patients are
particularly susceptible to EPS, even when exposed to neuroleptics for a short period
(e.g., within the first month of treatment). In regard to patients within a more
representative age range (mean age of 28), Oosthuizen and colleagues (2003) have shown
that even minimal exposure to neuroleptic treatment can cause substantial EPS in a
relatively short period of time (i.e., at one year follow-up).
The emergence of the newer atypical neuroleptics has been accompanied by an
assumption that these newer drugs reduce the risks of EPS. The summed research
suggests that approximately 50-90% of all patients treated with the older typical
neuroleptics will experience some form of EPS. In contrast it has been estimated that as
many as 20-50% of atypical recipients will suffer the consequences of drug-induced EPS
(Malla et al., 2004). Two recent studies report no significant differences between the
newer and older drugs in regard to neurotoxicity (Bonelli et al., 2005; de Leon, in press).
Therefore, while the reduced risks are questionable, it is clear is that the incidence rates
of EPS associated with the newer atypical drugs are still quite substantial.
If there are reduced risks of EPS enjoyed by the atypical neuroleptics, they are
potentially outweighed by the unique tendency of the atypicals to contribute to obesity
(Meyer, 2001), cardiovascular disease (e.g., Osby et al., 2000), diabetes (e.g., Dixon et
al., 2000) and dysmetabolic syndrome (e.g., McEvoy et al., 2005). The latter,
dysmetabolic syndrome, is defined by clinical features that include obesity, abnormal
density of lipoproteins, elevated fasting triglycerides, hypertension, and impaired fasting
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glucose or overt diabetes mellitus. While diabetes represents a disease entity with a high
risk for cardiovascular disease, dysmetabolic syndrome’s cluster of physiological
symptoms is deemed an even more dangerous precipitant to heart trouble.
McEvoy et al. (2005) found that compared to a matched normative sample, male
and female schizophrenics exposed to atypical antipsychotics are respectively 138% and
251% more likely to have dysmetabolic syndrome. A staggering 41% of all schizophrenia
patients in this sample developed dysmetabolic syndrome. In a 10-year longitudinal
study, Henderson and colleagues (2005) report similar results specifically related to the
atypical drug clozapine. In addition to these dymetabolic syndrome studies illuminating
the greater risks neurolepticized schizophrenics face in regard to the gradual
development of heart disease, Sabine and colleagues (2004) report neuroleptic use is also
associated with sudden cardiac death, even at low doses.
In regard to sexual dysfunction, typical and atypical drugs have been shown to
produce prolactin imbalances regularly linked to infertility (e.g., Alexiadis, Whitehorn,
Woodley, & Kopala, 2002). Older and newer neuroleptics have also been linked to
decreased libido, erectile and ejaculatory dysfunction, gynecomia, and amenorrhea (e.g.,
Bobes et al., 2003).
Recent studies have replicated results that have found a positive association
between neuroleptic use and mortality. For example, Healy and colleagues (2006) present
data indicating the greater risks of suicide faced by schizophrenics treated with typical
and atypical neuroleptics compared to non-medicated schizophrenics. The investigators
compared detailed asylum records of psychotic admissions in Victorian North Wales
(1875-1924), within the same geographic locale to similar records kept between 1994 and
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1998. The authors found a startling result: patients treated with the latest antipsychotic
drugs had a 20-fold increased risk of suicide compared to those treated without drugs in
the Victorian era. Data from the British Medicines Healthcare Regulatory Agency
(Alliance for Human Research Protection, 2006) confirm that antipsychotics (as well as
antidepressants) are implicated in the greatest number of suicides and suicide attempts in
the United Kingdom. These data further suggest the decline in mental health care
associated with medication-only treatments.
Joukamaa and his Finnish colleagues (2006) also found an association between
typical neuroleptic use and mortality in schizophrenia in their 17-year longitudinal study.
They found that schizophrenic individuals in general have a 1.29-to-1 relative risk of
mortality compared to normal controls. Thus, just having schizophrenia puts you at risk
above the general population. This is neither surprising nor unexpected. However,
following adjustment for age, gender, somatic diseases and other potential risk factors for
premature death, the authors found that “[t]he number of neuroleptics used at the time of
the baseline survey showed a graded relation to mortality” (p. 122). Specifically, the
relative risks for people with schizophrenia taking one, two, or three or more neuroleptics
at baseline were (95% CI) 2.97, 3.21, and 6.83, respectively. The association remained
stable throughout the 17-year follow-up period. According to these results, neuroleptics
may be more than ineffective, they may be dangerous. These findings replicate previous
studies that similarly found an association between polypharmacy and increased mortality
rates with both typical and atypical neuroleptics (Bralet, Yon, Loas, & Noisette, 2000;
Morgan et al., 2003; Osby, Correia, Ekbom, & Sparen, 2000; Reilly, Ayis, Ferrier, Jones,
& Thomas, 2002; Wallington, Youssef, & Kinsella, 1998).
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One of the predominant features of schizophrenia is disorganized thinking. As
such, medications meant to treat schizophrenia should help rather than harm cognition.
However, this is not always the case. Kasper and Resinger (2003) found that neuroleptics
actually contribute to cognitive impairments rather than ameliorate them. Minzenburg
and colleagues (2004) found that neuroleptic medications negatively impacted visual
attention, general intelligence, and short-term declarative memory after controlling for
psychopathology and cognitive ability. A variety of studies document the relationship
between neuroleptic use and executive functioning and working memory (Gilbertson &
van Kammen, 1997; Mehta, Manes, Magnolfi, Sahakian, & Robbins, 2004; Papageorgiou
et al., 2003; Sweeney, Keilp, Haas, Hill, & Weiden, 1991; Vitiello et al., 1997), sustained
attention and arousal (Cassens, Inglis, Appelbaum, & Gutheil, 1990; King, 1994),
reaction times (Ridout & Hindmarch, 2003), information processing (Brebion, Amador,
Smith, & Gorman, 1998), fine motor coordination (Cleghorn, Kaplan, Szechtman,
Szechtman, & Brown, 1990), temporal processing (Rammsayer, 1997), latent inhibition
(McCartan et al., 2001), and procedural learning (Scherer et al., 2004).
Clearly, the physiological and cognitive side-effects of neuroleptic treatment are
serious consequences needing to be factored into our general treatment approach to
schizophrenia, along with the fact that there is no empirical evidence documenting any
deleterious side-effects of psychotherapeutic interventions. Therefore, it is not
unreasonable to suggest that psychotherapy need only fare equal to, or of course better
than, neuroleptics for treating schizophrenia since the neuroleptic side-effects place the
medications at a serious clinical disadvantage. In this vein, I will now explore the
empirical effectiveness of psychodynamic psychotherapy.
64

Section IV: The Effectiveness of Psychodynamic Psychotherapy of Schizophrenia
The “tragedy” of schizophrenia in our modern mental health care system is that
we know of treatments that work – namely, psychodynamic psychotherapy - but very
rarely offer adequate training or resources for this approach (Karon, 2003, p. 89).
Although there are a number of psychodynamic perspectives that inform the treatment of
schizophrenia, it is possible to extract a number of common threads that bind these
approaches together. Some of the more prominent psychodynamic clinicians, theorists,
and researchers contributing to these core ideas include Arieti (1974), Boyer, Giovacchini
& Hoedemaker (1967), Fromm-Reichmann (1950), Karon & Vandenbos (1981), Searles
(1960, 1965), Will (1968) and Sullivan (1953, 1962).
To start, what psychodynamic psychotherapy of schizophrenia is not is classically
psychoanalytic. That is, clinicians working with this severe population do not have
patients lying on a couch, facing away from them, or promote regression via a general
stance of clinical abstinence and neutrality; nor do therapists aggressively provide genetic
or defense interpretations as would be expected in the treatment of a neurotic-level
patient. This is an important point because it is generally assumed by psychiatrists and
non-psychodynamic therapists that there have been no amendments to the original
Freudian approaches/tenets in regard to schizophrenia. This misunderstanding has been
most recently repeated in the PORT study’s out-of-hand rejection of the use of
psychodynamic therapies based on the faulty notion that such treatments promote
“regression and psychotic transference” (Lehman & Steinwachs, 1998, p. 8). Since the
PORT was convened to review the clinical literature to create treatment
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recommendations for practicing psychiatrists and psychologists this misperception is
extremely significant. Fortunately, Ver Eecke (2003), Gottdiener and Haslam (2003), and
Silver (2003) each provide a clear, theoretical and empirical-based critique of the
mistaken conclusions of the PORT.
The contemporary psychodynamic approach to schizophrenia is more accurately
depicted to include the following core tenets:
1)

A patient has a narrative that is highly relevant to his or her
psychological suffering. It is imperative to consider the role of the
patient’s early environment/experiences as a partial contributor to the
patient’s interpersonal difficulties, preferred defensive style, and overall
symptomatic distress. Another way to express this idea is to consider a
patient’s life events, both positive and negative, as contributors to each
patient’s idiosyncratic (and often psychotic) attempts to adapt to the
complexities of our social, vocational, and interpersonal world.

2)

The therapist should listen seriously and respectfully to each
individual’s subjective affective and cognitive experience, no matter
how seemingly bizarre or ‘irrational’.

3)

The therapist should attempt to understand the symptoms of
schizophrenia as symbolic communications of unresolved and very
distressing interpersonal dilemma(s) stemming from a core confusion in
which “one cannot maintain a border between where [s/]he ends and
where objects [i.e., other people] and their internalized representations
start” (Volkan, 1995, p. 27). These object relations, that is, one’s
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internal representations of self/other and external patterns of relating,
are believed to be exacerbated by, and a product of, an internal world
full of split (i.e., conflicting affect states held apart from each other) or
even fragmented self- and other-images often saturated with powerful,
un-neutralized affect states.
4)

The internal situation referred to in #3 results in a fairly constant paniclevel anxiety that leaves the schizophrenic patient feeling as if he or she
is in continuous existential danger. This internal dread is often
externalized and obscurely communicated in delusional and
hallucinatory symptoms often of a paranoid nature. Psychodynamic
theory understands these psychotic symptoms, as well as acute
withdrawal from social relations, as defenses (or, poorly adaptive
solutions) used to protect the schizophrenic patient from powerful
internal affect states that are psychotically distorted as external threats.

5)

Due to its understanding of the intensity of affects underlying defenses
in schizophrenia, psychodynamic therapy is designed to assist patients
develop more adaptive defenses/solutions, as well as conscious insight
to help patients more realistically express their internal experiences, and
“convert raw anxiety into sublimated cohesive” self understanding
(Silver, Karon, & Koehler, in press, cited in Silver, 2003, p. 330).

6)

Karon and Vandenbos (1981) outline three essential functions of the inthe-room relationship. First, the therapist-patient relationship should
provide sufficient protection and gratification to overcome the
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conscious resistance the patient has to engaging the therapeutic process.
Due to a history of very troubled interpersonal relationships, the
therapist needs to present him- or herself as “a strong, protective, more
gratifying figure than [s/]he would be in the therapy of [healthier, nonpsychotic] patients” (p. 145). Second, that which transpires verbally and
non-verbally in the room between the schizophrenic patient and
therapist is highly relevant to his or her troubling patterns of
internal/external interpersonal experiences. Thus, within the therapeutic
relationship a schizophrenic patient, similar to any other patient,
“relives feelings and experiences from the past [i.e., transference]…thus
providing an enormous source of information as to what [the patient’s]
life history and problems were truly like” (p. 146). This type of
information is intended to allow for slow resolution/understanding of a
particular patient’s core anxiety laden conflicts. Third, the therapist’s
sustained curiosity, warmth, desire to help, and refusal to accept
therapeutic failure should function as a reliable model for identification.
Identifying with the therapist in this way is intended to modify the
unusually harsh super-ego’s common to schizophrenia patients.
7)

Psychodynamic theory holds that under enough stress, especially in the
context of a limited support system, anyone is susceptible to degrees of
psychoticism.

8)

Psychodynamic approaches assert that schizophrenia is not solely a
‘chemical imbalance’ nor is it a degenerative brain disease. Rather,
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schizophrenia is a complex and extreme biopsychosocial reaction to
troubling real-world experiences.
9)

Therapists working with schizophrenic patients must have a high
tolerance for confusion and frustration and be free of the need to derive
narcissistic gratification from the patient’s therapeutic efforts and/or
success (Bachmann, Resch, & Mundt, 2003).

Beyond psychodynamic psychotherapy there is growing evidence that other modalities,
such as cognitive-behavioral treatment (e.g., Turkington et al., 2006), residential-based
milieu treatment (e.g., Mosher, Vallone, & Menn, 1995), social learning treatment (e.g.,
Paul & Lentz, 1977), Open Dialogue treatment (Seikkula, Alakare, & Aaltonen, 2000;
Seikkula et al., 2003) and family treatment (e.g., Schindler, 1980) are effective
alternatives adjunctive to or independent of medication treatment. For the sake of brevity
and because it reflects the empirical component of this dissertation project, this review
will focus solely on the empirical literature exploring psychodynamic and
psychodynamically-informed treatments.
Research Investigating the Psychodynamic Psychotherapy of Schizophrenia
Due largely to the drug-bias in the modern mental healthcare system there have
been very few randomized studies that explore psychotherapy without adjunctive
medication (Jackson, 2005). However, of the four that do exist the overall results indicate
the promise of psychodynamic work with schizophrenia, despite significant limitations
impacting two of these studies in particular (for a review see Karon, 1989).
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Carl Rogers and colleagues (1967) performed a randomized clinical trial
comparing person-centered therapy to a neuroleptic-only treatment approach. Although
person-centered therapy is not psychodynamic, many of its core tenets are deeply
influenced by and comparable to a contemporary psychodynamic approach – especially
in regard to the treatment of the more severely ill. For example, Rogers’ approach,
similar to any psychodynamic approach, focuses a great deal of attention on the in-theroom relationship. Rogers et al. write, “…the most essential ingredient for change will be
found in the attitudinal qualities of the person-to-person relationship (p. 92).
In this study, there were 16 early phase schizophrenics and 16 chronic
schizophrenics. After matched pairing, the schizophrenic patients were randomly
assigned to each of two treatment groups: psychotherapy-only and neuroleptic-only.
Therapy was given twice a week for up to 2.5 years. Outcome was assessed by blind
reviewers, the therapists and the patients themselves. All significant findings favored the
psychotherapy group including improved interpersonal relationships, enhanced capacity
to openly experience and express their emotions, and better ability to “face their
environment and themselves” (cited in Irwin, 2004b, p. 100). Importantly, the
psychotherapy group spent an average of 112 fewer days in the hospital following the end
of the psychotherapy phase of the study. Therapeutic alliance defined by genuineness,
empathic attunement, and affective congruence was positively related to outcome.
Psychotherapy patients who did not experience as positive a therapeutic relationship did
not fare as well by the study’s end, suggesting the important mutative impact of the
patient-doctor alliance. Limitations of the study included small sample size and lack of a
placebo group. Strengths included treatment fidelity which was measured and rigorously
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monitored. That is, the research and clinical supervisors of this study were committed to
the psychotherapy component of the study.
May and colleagues (1976, 1981) randomized 228 early episode individuals
suffering with schizophrenia to one of five treatments: psychodynamic psychotherapy
without medication, psychodynamic psychotherapy with medication, medication-only,
ECT, or milieu therapy. All groups received milieu therapy and therefore the milieu
group served as the control cohort. Psychotherapy was provided for two years at two
times per week. Outcome measures included number of days hospitalized, social
competence, and global functioning derived from patient interviews, families, social
workers and hospital records. After two years the only significant difference found was in
number of hospital days, favoring the medication-only group; after 3, 4, and 5 years there
were no significant differences found. Karon (1989) extensively critiques the quality of
psychotherapy provided in this study based on the supervisors’ reported lack of
experience and negative expectations of the utility of psychotherapy for schizophrenia.
Even with these limitations handicapping the psychotherapy patients, the medication-only
individuals, in general, did not outperform them. Other limitations also include the lack
of a placebo group and lack of blinding for most assessments (which likely deleteriously
impacted the psychotherapy group due to negative treatment expectations held by the
research team).
Grinspoon and colleagues (1972) randomized 41 people diagnosed with chronic
schizophrenia into three groups: 21 remained in the hospital where they continued
neuroleptics; 10 were given placebo for 13 weeks and then restarted on neuroleptics; and
10 were given placebo for 13 weeks and then provided with psychodynamic
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psychotherapy. At five years two trends (p = .07) favoring the psychotherapy patients
were detected, including decreases in psychotic symptoms and better capacity to adapt to
life outside of the hospital. Perhaps due to their inability to shed their drug bias the
researchers referred to the improvements in the psychotherapy group as “an artifact” (p.
1126). Karon and Vandenbos (1981), Karon (1989), as well as Irwin (2004b) outline
substantial limitations of this study. First, over half of the psychotherapy patients had
previously received at least one round of ECT, insulin shock, or both. As Karon and
Vandenbos write, “Psychotherapists experienced with treating schizophrenic patients
have doubts about attempting psychotherapy with patients who have had ECT or insulin
comas [due to the organic damage resulting from such intrusive treatments]…No serious
study of psychotherapy would include such patients…” (p. 380). Beyond this, the
therapists used in this study had very little experience with treating schizophrenia or
patients from the cultural and socioeconomic group of those included in the project. In
fact, retrospectively, most of the therapists in this study explicitly expressed doubt about
the quality of the psychotherapy provided in this study (see Karon, 1989). Lastly, the
drug washout time of 13 weeks is not considered adequate (Breggin & Cohen, 1999),
thereby making this a study of drug withdrawal as much as anything else. Despite these
limitations negatively impacting the psychotherapy patients, these individual fared
relatively well with the aid of psychodynamic psychotherapy.
Karon and Vandenbos (1981) completed the last randomized trial of
psychodynamic psychotherapy of schizophrenia of the 20th century in the late 1960’s. It
is this study from which the current project’s data are derived. As reported above, at the
conclusion of their 20-month investigation the researchers found that patients receiving
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psychotherapy significantly outperformed individuals receiving medication-only on three
of four instruments assessing patients’ thought disorder, on a blindly rated clinical status
interview, and days spent in the hospital due to mental dysfunction. On the fourth
measure of thought disorder, differences between the psychotherapy and medication-only
patients approached significance (p = .07). Individuals of the medication-only group did
not fare better in any area assessed. More specific details of Karon and Vandenbos’
investigation will be explored in the ‘Methods’ section below.
Gottdiener & Haslam (2002) recently conducted the first comprehensive metaanalytic review of individual psychotherapy of schizophrenia, including in their analysis
between- and within-groups designs as well as psychotherapy designs with or without
adjunctive medication. These important inclusions have been missing from past metaanalyses investigating schizophrenia outcome research (Cormac, Jones, & Campbell,
2002; Malmberg & Fenton, 2001; Mojtabai, Nicholson & Carpenter, 1998; Smith, Glass,
& Miller, 1980). Gottdiener and Haslam examined studies exploring cognitivebehavioral, psychodynamic, and non-psychodynamic supportive therapies.
Gottdiener & Haslam (2002) report an overall corrected effect size of r = .36
across the three treatments. Psychodynamic (r = .39) and cognitive-behavioral (r = .41)
treatments with and without medications were found to be equally effective. Nonpsychodynamic supportive therapy exhibited a relatively smaller effect (r = .27; no
significance test was conducted). Despite the PORT recommendations (Lehman &
Steinwachs, 1998) and other empirically unsupported admonishments (e.g., Drake &
Sederer, 1986) against the use of psychodynamic therapy, insight-oriented therapy fared
quite well relative to other psychotherapy modalities.
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As the entirety of this dissertation project has made clear until this point, there is a
strong biopsychiatric belief that neuroleptics are the most effective form of treatment for
schizophrenia. However, Gottdiener and Haslam (2002) report that use of medications
did not impact effect sizes at all. That is, when medications were used with
psychotherapy the effect size was identical to when medication was withheld (r = .31). Of
course, the participants being treated without medications were free of the various sideeffects caused by these potent chemical agents. In sum, similar to the few randomized
trials reported earlier, this meta-analysis provides additional evidence that
psychodynamic psychotherapy is safe, effective, and without doubt worthy of additional
empirical attention.
In concluding this introduction, based on 1) the philosophically and empirically
untenable degenerative and psychotoxicity assumptions; 2) significant flaws in the FDA
approval process and the RCT design in general for use in schizophrenia research; 3) the
empirically documented ineffectiveness of typical and atypical neuroleptic treatments; 4)
severe side-effects of neuroleptic treatments; and 5) the effectiveness of psychodynamic
psychotherapy, one is left seriously reconsidering the wisdom of a medication-only
treatment approach in lieu of existing alternatives. I will now continue with the empirical
portion of this dissertation project.
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II. METHODS
Section V: Pre- to Post-Treatment Change in the Object Relations of Schizophrenic
Patients
As mentioned, the experimental design utilized in the original study conducted by
Karon and Vandenbos (1981) called for the selection of schizophrenic patients to be
assigned on the basis of a random number table to one of three treatments: 1)
psychotherapy without medication (Psychotherapy-only, A); 2) psychotherapy with
adjunctive medication (Mixed, B); and 3) routine hospital treatment consisting primarily
of phenothiazines (i.e., typical neuroleptics; Medication-only, C). The adjunctive
medication provided to individuals of the Mixed group (B) was discontinued after the
first few weeks of the study. Overall, 36 patients were evenly distributed among the three
treatment groups. The small number was necessary in order to be careful about gathering
detailed and rigorous data throughout the 20-month study. The small numbers in the
psychotherapy groups (A and B) also allowed for more efficient ‘quality control’ of
psychotherapeutic treatment by experienced supervisors. This was particularly important
because, as mentioned earlier, the quality of psychodynamic therapy provided in past
randomized studies has been seriously called into question in regard to the quality of
training the therapists had, the therapist’s specific experience with psychotic patients, and
researcher bias (Karon, 1989). Due to incomplete data available for the Mixed group (B),
this cohort has been removed from the current study. Although this is an unfortunate loss
of potentially useful and interesting data, the primary and unique aspect of the experiment
is the assessment of a completely non-medicated group. That is, while there are studies
exploring mixed treatment approaches (see for a review Gottdiemer & Haslam, 2002),
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there are as far as could be determined no published U.S.-based studies in the last 25
years that utilized a fully non-medicated group.
Clinical Participants
All inpatient admissions to the Detroit Psychiatric Institute (DPI) were reviewed
for possible inclusion in the project. Evaluation for selection was solely in terms of
meeting the selection criteria discussed below. Selection was made by using the same
criteria and research personnel throughout the entirety of the project. Patients were not
selected by regular hospital staff or with an eye to whose patients they might become.
The intent to obtain schizophrenic patients with no organic pathologic condition or
previous hospitalizations required adequate case histories and thorough medical
examinations before selection into the project. This process required two weeks for each
case. Patients were not assigned to treatment groups until there were three patients who
had completed preliminary medical and diagnostic examinations so that the ‘set’ could
then be randomly assigned. If a patient was discharged before assessment was complete
that patient was replaced as a potential project patient by another patient who met the
requisite criteria and was still hospitalized.
The admission rate to the DPI ward was approximately 5,000 patients per year
throughout the 1960s (Karon & Vandenbos, 1981). Hence, in any given week a pool of
about 100 potential research patients would be reviewed using the initial criteria.
However, roughly two-thirds of these patients were discharged within two weeks,
therefore precluding completion of the extensive medical and diagnostic assessment. As a
result, the actual pool of potential research subjects was about 35 per week. Only one set
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of three patients was selected in a given week. All the patients were selected within a 4month period. Any differences in patient characteristics reflect possible week-to-week
fluctuation in admissions and therefore were well within the bounds to be expected from
random variation.
Patients utilizing services at DPI were primarily poor, inner-city AfricanAmericans. The initial selection process was to select acutely ill (i.e., not chronic) and
clearly schizophrenic patients. Six criteria were mandatory for inclusion. The first and
most important criterion was that the patient needed to be unquestionably schizophrenic.
The diagnoses of patients in the study were made by two independent research personnel
(clinical psychologists) with considerable experience in the treatment and diagnosis of
schizophrenia, neither of whom was connected with treatment of the clinical patients.
DSM-II criteria and medical screening for organic illnesses were utilized to guide the
diagnostic process. Both experts had to agree with the schizophrenia diagnosis for the
patient to be included. Further, the DPI Ward Chief as well as an independent psychiatric
resident also had to concur with the diagnosis for the patient to be included in the project.
Criteria two through six included: 2) onset of blatant psychotic symptoms within 3
months prior to admission; 3) first admission; 4) no history of ECT or insulin shock
treatment; 5) no organic brain damage; and 6) no history of alcoholism or drug addiction.
Of particular relevance to this sample, Dunham (1965) found that the median time
between onset of blatant psychotic symptoms and the first presentation to treatment was
34.5 months for poor, inner-city African-Americans. Since these patients tended to be ill
for some time prior to admission at DPI, criterion three (i.e., “first admission”) is
misleading as these patients were more severely impaired and chronic compared to other
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first admissions derived from less impoverished communities. Severity of illness was best
observed on the pre-treatment scores on the Drasgow-Feldman Visual Verbal Test (VVT;
Feldman & Drasgow, 1951) for which 29 of 35 patients scored at or below the norms for
chronic schizophrenic individuals. Importantly, VVT normative data were drawn from
schizophrenic patients hospitalized for 3 or more years. Thus, across groups, these poor,
generally African-American patients exhibited a very severe level of chronicity atypical
for first admission schizophrenics. Exacerbating the severity was that initial screening
failed to reveal 11 previous hospitalizations (Psychotherapy-only = 4, Mixed = 2,
Medication-only = 5). Patients and their families reasoned correctly that a previous
hospitalization leads to worse treatment in general and therefore they actively concealed
this information.
Despite the attempt at careful medical screening, some medical problems were not
accurately revealed during the initial screening process. Four dramatic instances
occurred. Two catatonic patients died of embolisms. The first died before randomization
had occurred and was therefore replaced without jeopardizing random assignment. The
second patient (a female in the Psychotherapy group treated by a trainee) died following
group assignment. She was therefore not replaced as such an assignment would not be
purely random. A female patient being treated by the Psychotherapy group supervisor
(Karon) was eventually diagnosed with multiple sclerosis despite being originally cleared
by the neurology and internal medicine services. It was only after psychotherapy
improved her thought disorder, reality testing and interpersonal distress that this patient’s
remaining motor impairments (this patient had a gait all along) were properly understood
as symptomatic of multiple sclerosis. Since the patient was indeed clearly schizophrenic
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and the two sets of symptoms followed independent courses, this patient was included in
the data. Karon and Vandenbos (1981) found that analyses were not significantly altered
by exclusion of this patient and so she will remain in the proposed study as well.
Another patient (a male in the Psychotherapy group treated by a trainee) initially
denied a history of drug abuse. However, during the course of psychotherapy this
patient’s verbalizations revealed a possible history of addiction. Subsequent collateral
contacts with the patient’s girlfriend and family revealed that for many years he had taken
seconal, Dexedrine, and nutmeg in daily irregularly large doses sufficient to produce
brain damage. This patient was excluded from the data analyses in light of the
inappropriate selection for the project. A third patient was excluded from the treatment
because of grossly unprofessional staff interference described in detail in Karon and
Vandenbos (1981). In sum, the Psychotherapy-only group lost three patients: one patient
died from an embolism, one was excluded due to a previous addiction history, and a third
was excluded because of gross staff interference. Therefore, the original analyses
included nine subjects in the Psychotherapy-only group, and 12 in the Mixed and
Medication-only groups (total n = 33). Thus, the proposed study utilizing only the pure
groups will have a final n-size of 21 (Psychotherapy-only = 9; Medication-only = 12).
Assignment of patients to experienced and inexperienced therapists was on a
rotation basis. Psychotherapy supervisors did not select which patients with whom they
would work. Psychotherapy supervisors were assigned two research patients previous to
assignment of patients to trainees. These cases served as training cases and were viewed
on closed-circuit TV and subsequently discussed.
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Therapists
There was one experienced supervisor for each of the psychotherapy treatment
groups. Each supervisor ultimately treated four patients. ‘Experienced’, as used in this
study, means approximately 10 years of experience specifically treating schizophrenic
patients (i.e., not merely doing psychotherapy but treating schizophrenic patients). Both
supervisors also had lengthy experience working with poor, inner-city African-American
patients. The psychology interns and psychiatric residents had three months to one year
of general practicum or residency experience before the initiation of the project. In
addition to supplemental texts designed to inform (though not manualize) treatment, the
trainees watched via closed circuit TV the beginning of the treatment of two patients by
their respective group supervisor before they began to work with their own patients. To
facilitate training, trainees’ early sessions were viewed on closed circuit TV by the
supervisor, as well as the other group trainees. In the latter phases of the study,
conventional individual supervision sessions were held. Trainees were monetarily
compensated throughout most of the study. At mid-project (approximately 12 months)
payments were suspended due to an intra-professional rule change precluding students
from accepting monetary compensation while matriculating. Trainees agreed to work for
several months without pay until the project supervisors were able to reinstitute
payments. It is possible that withheld payments may have affected motivation of trainee
therapists and impaired the effectiveness of their performance during the period of
withheld compensation. All project therapists were Caucasian, reflecting the ethnic
composition of the hospital’s professional staff and of the clinical psychology and
medical students. Minority students were unavailable in the programs in which the
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trainees matriculated. Medical and psychology students were evenly distributed among
the psychotherapy treatment groups to minimize professional jealousies as a
contaminating factor.
Explanation of Psychotherapeutic Treatment
Because the Mixed group will not be investigated in this proposed study, only the
technique and theory of the Psychotherapy-only group will be presented. The
Psychotherapy-only group used psychodynamic psychotherapy without medication. The
derivative of psychodynamic therapy utilized with these patients was largely influenced
by Karon’s (1994; Karon & Vandenbos, 1981) interpretation of the theory and technique
of Sullivan (1953, 1962) and Fromm-Reichmann (1950). Briefly, there are a few central
tenets of Karon’s approach largely in tune with the core psychodynamic principles
discussed earlier. The first critical issue is how to come into meaningful contact with the
patient. That is, at the very onset of treatment emotional contact must be established.
Schizophrenic individuals are good at avoiding authentic contact with people, so in the
initial sessions it is imperative for the therapist to establish his or her existence, desire to
help, as well as convey understanding of the patient’s confusing and frightening
experience. The immense dread often experienced by the patient is diminished if the
therapist provides attention, interest, and absolute seriousness in the meaning of the most
frightening psychotic experience of the patient (e.g., projections, hallucinations,
delusions). There are also two general principles of interpretation adhered to in this
approach, both intended to generate insight promoting change.
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The first principle is to interpret from the surface in the sense of exhausting reality
factors and realistic explanations first. Few patients are willing to consider
psychodynamic factors until commonsense explanations are found wanting. Driving this
principle is the basic idea that a therapist interprets what he or she believes the patient can
make use of at that time. The second general principle is that the therapist never does for
a patient what the patient can do for him- or herself. An insight discovered by the patient
is far more potent than a similar interpretation from the therapist. In other words, value
the meaning-making processes inherent in a patient’s tendency towards health. In terms
of therapist activity, Karon and VandenBos (1981) assert that it is not accurate empathy
or understanding that produces change in patients, but rather the therapist’s concerted
attempts at empathy and understanding (whether or not successful). Also, Karon’s
approach highlights the importance of the therapist’s capacity to tolerate confusion, due
not only to the often obscure and entangled thinking of the patient, but also because
conveying confusion as a tolerable and all-too-human experience is an invaluable
offering to a person suffering with schizophrenic processes. In sum, Karon’s approach to
psychotherapy with schizophrenic patients is to value and encourage the totality of
patients’ successful and troublesome encounters with self and world, to be tolerant and
kind, create hope, to encourage self-understanding, and perhaps most of all, to be
stubborn in not accepting therapeutic failure.
Measure
Social Cognition and Object Relations Scale (SCORS). Westen's (1995;
Hilsenroth, Stein, & Pinsker, 2004) SCORS is a narrative-based object relations measure
82

designed to assess a variety of dynamic personality features beyond the overt presentation
of the patient. The SCORS consists of eight clinician-rated dimensional variables that
examine the affective and cognitive aspects of an individual's object relations. This
multivariate approach allows clinicians to discern higher from lower areas of object
relational functioning. Such an approach is clinically useful considering that people
generally possess interpersonal strengths and weaknesses contingent upon the content of
the schema certain social situations activate (e.g., emotional intimacy schema, authority
schema). Each of the eight SCORS variables is scored on a 7-point anchored rating scale
where lower scores (e.g., 1 or 2) indicate greater pathology and higher scores (e.g., 6 or
7) indicate greater psychological health.
The eight SCORS subscales include: 1) “Complexity of Representations” (COM)
assesses the richness of a patient’s representations of self and others, as well as his or her
abilities to integrate both positive and negative attributes of self and others; 2) “Affect
Tone of Representations” (AFF) assesses a patient’s positive and/or negative expectations
from others in relationships and how the patient describes relationships; 3) “Emotional
Investment in Relationships” (EIR) identifies the patient’s level of commitment and
emotional sharing in relationships; 4) “Emotional Investment in Values and Moral
Standards” (EIM) distinguishes between patients who show no remorse for selfish actions
versus those who think about moral questions in genuinely compassionate and thoughtful
ways; 5)“Understanding of Social Causality” (USC) assesses how well a patient
understands why people do what they do; 6) “Experience and Management of Aggressive
Impulses” (AGG) assesses a patient’s ability to control and appropriately express
aggression; 7) the “Self-Esteem” (SE) variable assesses the affective quality of patient’s
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self-representation; and 8) “Identity and Coherence of the Self” (ICS) assesses a patient’s
level of integration and goal-directed behavior.
Huprich and Greenberg (2003) and Stricker and Gooen-Piels (2004) provide an
extensive review of previous SCORS research, therefore the following will be an
illustrative rather than exhaustive presentation of the SCORS’ reliability and validity. The
SCORS has exhibited good to excellent inter-rater reliability when utilized to rate TAT
narratives (Ackerman, Clemence, Weatherill, & Hilsenroth, 1999; Ackerman, Hilsenroth,
Clemence, Weatherill, & Fowler, 2000; Fowler, Ackerman, Speanburg, Bailey, &
Blagys, 2004), relational and self-statements expressed to clinicians in psychotherapy
sessions (Peters, Hilsenroth, Eudell-Simmons, Blagys, & Handler, 2006), early memory
narratives of adult clinical outpatients (Fowler, Hilsenroth, & Handler, 1995; Slavin,
Stein, Pinsker, & Hilsenroth, in press), semi-structured interview data (Porcerelli, Cogan,
& Hibbard, 1998), and stories elicited by the Picture Arrangement subtest of the WAIS-R
(Segal, Westen, Lohr, & Silk, 1993).
Convergent validity has been demonstrated in a number of studies comparing the
SCORS to validated research instruments such as the Rorschach Inkblot Method
(Ackerman, Hilsenroth, Clemence, Weatherill, & Fowler, 2001; Hibbard, Hilsenroth,
Hibbard, & Nash, 1995) and the DSM-IV Axis V scales (Peters et al., 2006). Previous
studies have found the SCORS useful for understanding affective aspects of
psychopathology (Hibbard et al., 1995), patterns of psychotherapy continuation
(Ackerman et al., 2000), personality change in treatment-refractory inpatients (Fowler et
al., 2004); interpersonal components of victims of childhood sexual abuse (Callahan,
Price, & Hilsenroth, 2003; Slavin et al., in press), and differentiating borderline
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personality disorder outpatients into subgroups (Tramantano, Javier, & Colon, 2003). The
SCORS has also shown the capacity to discriminate between borderlines, major
depressives, and normals (Westen, Lohr, Silk, Gold, & Kreber, 1990), MMPI diagnosed
psychotics, sociopaths, and normals (Porcerelli et al., 1995), inpatient suicide attempters
and non-attempters (Kaslow et al., 1997), as well as cluster B and cluster C personality
disorders (Ackerman et al., 1999). The SCORS has also predicted treatment response for
PTSD diagnosed inpatients (Ford, Fisher, & Larson, 1997) and psychosocial adjustment
approximately two years after the death of a spouse (Field, Sturgeon, Puryear, Hibbard,
& Horowitz, 2001).
Interrater reliability of each of the SCORS subscales was evaluated utilizing a
one-way random effects model intraclass correlation coefficients (ICC [1,1]; Shrout &
Fleiss, 1979) from 20 randomly selected pre- or post-treatment protocols across all three
groups. Raters were two advanced doctoral students enrolled in an American
Psychological Association approved clinical Ph.D program. Prior to rating the SCORS
both raters participated in group training in which scoring guidelines were reviewed and
supervised by a licensed Ph.D Clinical Psychologist. Upon completion of the reliability
scoring, raters met to discuss any ratings that were separated by two or more points to
attempt to bring the scores to at least within one point of each other. This additional step
was necessary due to the degree of cognitive distortion and psychotic psychopathology
inherent in this schizophrenic sample. All protocols were coded to mask group affiliation,
name, gender, and time to ensure that ratings were blind throughout the entirety of
scoring for both raters. Table 3 reports interrater reliability for each of the SCORS’ eight
subscales. ICCs are considered to be excellent if greater than .74, good from .60 to .74,
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fair from .40 to .59, and poor if under .40 (Shrout & Fleiss, 1979; Fleiss, 1981). All
SCORS subscales were in the good to excellent range.
Explanation of Analyses
SCORS variables with appropriate unrestricted variance will be utilized in all
subsequent analyses. First, to assess the convergent and divergent validity of the SCORS
for use with a schizophrenic sample, Pearson rs were computed between each of the pretreatment SCORS variables and five criterion variables: 1) pre-treatment Clinical Status
Interviews (CSI); 2) verbal IQ as measured by the WAIS (Weschler, 1955); 3) total days
in hospital (controlling for treatment change) over the course of the 20 month
investigation; 4) age; and 5) years of education.
CSIs were conducted with each patient at pre-treatment by Karon and Vandenbos
(1981). The CSI is a clinician-rated indicator of overall health-sickness comparable to the
Global Assessment of Functioning scale found in the DSM-IV (APA, 1994). Similar to
the SCORS, higher CSI scores indicate healthier levels of functioning. Thus, it was
hypothesized that the CSI and all SCORS variables would exhibit a positive and
significant relationship.
Past research has found that variables COM and USC are the cognitive variables
of the SCORS measure, as opposed to the other SCORS variables that are deemed the
affective variables (Hibbard et al., 1995; Westen, 1995). Therefore, in regard to verbal
IQ, it was predicted that the SCORS’ cognitive variables COM and USC would be
positively and significantly related to verbal acuity as measured by the WAIS, thereby
indicating convergent validity. In contrast, in the service of assessing divergent validity,
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it was hypothesized that AFF, EIR, SE, and ICS would not exhibit a positive and
significant relationship, since these variables are designed to assess the affective
components of object relations and are theoretically distinct from IQ. Exhibiting
divergent validity of a narrative-based measure with verbal acuity is important to ensure
that the quality of narratives is more related to the construct under investigation (i.e.,
object relations) rather than to verbal skills.
In regard to the SCORS and total days in the hospital, it was hypothesized that the
relationship would be significant and in the negative direction. That is, the more days
spent in the hospital due to poor psychiatric functioning, the lower the pre-treatment
SCORS ratings. Lastly, in the service of divergent validity, it was hypothesized that age
and years of education would not be related to object relations. Pearson r correlational
coefficients are considered to represent a small effect from .1 to .3, a medium effect from
.3 to .5, and a large effect if greater than .5 (Cohen, 1988).
Utilizing paired-samples t tests, pre-treatment SCORS variables with appropriate
unrestricted variance were examined to determine within-group change. This analysis
assessed whether or not Psychotherapy or Medication treatment led to significant change
across each SCORS variable. T scores were converted to Cohen’s d effect size to
facilitate comparison between variables and groups and provide a commonly used
magnitude of effect coefficient. Cohen’s d values .2, .5, and .8 indicated small, medium,
and large effects, respectively.
Following the paired-samples t tests, ‘difference scores’ for each SCORS variable
were calculated for each SCORS variable at the group level (i.e., post-treatment minus
pre-treatment). Independent-samples t tests will be conducted to assess between-group
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differences for each SCORS variable. While these traditional outcome analyses allow for
determination of gross differences between treatment groups, they are not capable of
isolating individual patient change. To examine change at the individual patient level pretreatment SCORS variables with appropriate unrestricted variance were subsequently
examined using Clinical Significance (CS) methodology (Jacobson & Truax, 1991;
Jacobson, Roberts, Berns, & McGlinchley, 1999). Utilization of CS methodology
provides “valuable information on variability of outcome within each treatment condition
and a way of determining the practical importance of statistically significant differences
between groups” and will be used to “descriptively augment” group change examined
with the independent-samples t tests of ‘difference scores’ (Jacobson et al., p. 301).
Jacobson and colleagues (1999) write,
Group means…do not in and of themselves indicate the proportion of participants
who have improved or recovered as a result of treatment… Standard statistical
comparisons between groups seldom determine the practical importance of the
treatment effects… even effect sizes do not directly speak to clinical significance”
(p. 300).
In the CS methodology an individual patient is considered ‘Recovered’ if he or
she meets two criteria: 1) a Reliable Change Index (RCI) score that exceeds 1.96; and 2)
achieves an outcome score (on the SCORS subscale) that is 2 SDs greater than the
accepted normative data of the scale in question. Meeting only one or the other criterion
precludes a researcher from labeling the individual ‘Recovered’. Considering the acutely
severe presentation of the current patient sample and the increased time it took for these
patients to seek hospital admission, there are obvious concerns regarding regression to
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the mean (Fowler et al., 2004). As a result, the Edwards-Nunnally formula (Speer, 1992),
which was created to control for regression to the mean during the computation of RCI
scores was applied to adjust all pre-treatment mean scores.
Criterion 1, calculation of the RCI, is computed in a fashion that controls for
measurement error, therefore suggesting that the RCI score is both psychometrically
reliable and reflective of real change, rather than standard error of measurement. For our
study using the SCORS, a modification in the RCI formula was necessary because testretest reliability, which is unavailable for the SCORS, is most commonly used to
determine the standard error of difference (Sdiff) found in the denomination of the RCI
formula (Wise, 2004). Jacobson et al. (1999) propose utilization of alternative measures
of reliability for the calculation of Sdiff. Hilsenroth, Ackerman, Blagys, Baity, &
Mooney, (2003) and Fowler et al. (2004) have made use of this suggestion in two
recently published outcome studies by using ICCs as an alternative reliability coefficient
in calculating Sdiff. For the purpose of this dissertation project ICCs will be used in a
like manner.
In regard to criterion 2, just as there are no normative test-retest data for the
SCORS, there are also no available normative means for its subscales. Fortunately, other
authors have proposed (Bauer, Lambert, and Nielsen, 2004) and utilized (Fowler et al.,
2004; Hilsenroth et al., 2003) an alternative method for computing a post-treatment
outcome score cutoff point. This cutoff point is determined by taking the pooled pretreatment sample mean of each target variable (i.e., the SCORS subscale) and adding two
SDs. For example, if the pooled mean of the Complexity of Representations variable was
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2.01 with a SD of .67, the outcome score of this variable for an individual patient must
exceed 3.35 (i.e., 2.01 + [.67 * 2]) to meet the condition needed to satisfy criterion 2.
One last modification is necessary due to the severity of our sample. Wise (2004)
observed that it is unrealistic to expect a sample of severely disturbed patients to achieve
the clinically significant benchmarks of RCI > 1.96 and an outcome cutoff point two SDs
greater than the pre-treatment mean. As such, Wise (2004) recommended additional
criteria for both RCI scores and standard deviation cutoff points. Wise’s (2004)
alternative is termed ‘Positive Response’ and requires that a patient achieve an RCI >
1.28 (i.e., the 90% confidence interval for RCI) and an outcome cutoff point one SD
greater than the pre-treatment mean. In their study of treatment-refractory inpatients,
Fowler et al. (2004) utilized Wise’s (2004) alternative criteria in addition to Jacobson and
Truax’ (1991) original classification (RCI > 1.96 and SD > 2.0). Based on our severely
disturbed schizophrenic sample, the current evaluation has also focused on both change
estimates classified as ‘Recovered’ and ‘Positive Response’. Percentages of patients in
each group meeting these two criteria were computed for all six SCORS variables. Rates
of clinical regression follow the same criteria but in the opposite direction and they too
are reported. Examining regression (if any) is particularly significant due to the widely
held belief that psychodynamic psychotherapy of schizophrenia is dangerous and results
in clinical regression (e.g., Lehman & Steinwachs, 1998).
An additional manner in which to understand how the patients of the current
sample presented clinically at post-treatment can be accomplished by comparing posttreatment SCORS scores to alternative SCORS data derived from another study that
investigated a less disturbed sample. For such a purpose, Table 4 reports pre-treatment
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SCORS subscale data from a study investigating the object relations of a patient sample
seeking psychotherapy from a university-based mental health center (Peters et al., 2006).
Peters and colleagues reported that the “level of psychological/emotional distress of the
patients in this treatment program was primarily in the mild to moderate range of
impairment, as evidenced by the DSM-IV (American Psychiatric Association, 1994)
diagnostic categories, clinician rating scales, and self-report measures” (p. 618). Thus, if
the outcome SCORS ratings of any schizophrenic patients equal or exceed the SCORS
ratings of this markedly healthier sample, it can be cautiously suggested that, at posttreatment, the object relations of these patients are comparable to patients entering
psychotherapy with mild to moderate levels of distress. Providing this auxiliary
information is another manner by which to show whether or not schizophrenics receiving
medication–only or psychotherapy-only are capable of improving in a manner contrary to
the expectations set forth by the biopsychiatric model.
While comparing percentages of those patients meeting ‘Recovered’ and ‘Positive
Response’ criteria provide important clinical information, application of chi square
analyses would provide a measure of statistical significance for group differences.
However, to perform the necessary 12 chi square analyses for all six subscales testing for
group differences using ‘Recovered’ and ‘Positive Response’ criteria would greatly
increase the risk of making a Type I error. Ford and colleagues (1997) and Peters et al.
(2006) have previously used a composite object relations score as a variable. This
procedure was adopted for the present study to limit the number of performed analyses in
an attempt to minimize the possibility of a Type I error. SCORS-Composite (SCORS-C)
was calculated by simply summing each of the SCORS variables and dividing by the
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number of variables summed to produce a single 7-point object relations total score. RCI
scores and improvement status (‘Recovered’ and/or ‘Positive Response’) were calculated
using the same procedures described above for the individual SCORS subscales. Chi
square scores were converted to Cohen’s d effect size to facilitate comparison between
variables and provide a commonly used magnitude of effect coefficient.
Lastly, to statistically test for group differences in clinical change after
controlling for error measurement and regression to the mean, independent-samples t
tests were computed using RCI scores as the dependent variable and group assignment as
the grouping variable. Again, because the RCI score is both psychometrically reliable and
reflective of real change, rather than standard error of measurement or regression to the
mean, it is a particularly useful indicator of clinical change and a statistical improvement
over past outcome research that historically has not controlled for such artifacts. In this
way, independent-samples t tests using RCI as the dependent variable might be a more
reliable and accurate indicator of group change compared to the traditional ‘difference
score’ analyses also conducted in this study. T-scores were converted to Cohen’s d effect
size to facilitate comparison between variables and provide a commonly used magnitude
of effect coefficient.
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III. RESULTS
The EIM (SD = .22) and AGG (SD = .24) variables (combined groups) did not
exhibit suitable unrestricted variance at pre-treatment and were thus removed from
subsequent analyses. The SDs of the other six SCORS variables ranged from .49 - .81,
thus the SDs for EIM and AGG were observably restricted. As a result, only six of the
eight SCORS subscales will be utilized in all subsequent analyses (COM, AFF, EIR,
USC, SE, and ICS). There were no significant between-group differences for any of the
six pre-treatment SCORS variables or demographic variables (education, age, gender,
race) confirming the randomness of group assignments.
Convergent and Divergent Validity
Table 5 reports all convergent and divergent validity analyses utilizing the pretreatment SCORS ratings. As expected, the WAIS Verbal Scale IQ (n = 17) and the
SCORS’ COM (r = .52, p = .03) and USC (r = .45, p = .01) exhibited significant and
moderate to large effects, indicating that the SCORS’ cognitive variables were
appropriately related to verbal intelligence. In regard to divergent validity, as expected,
the SCORS’ affective variables were not related to verbal IQ, indicating that the SCORS
affective variables measure something distinct from verbal functioning. In regard to
convergent validity, the CSI (n = 21) and the pre-treatment SCORS variables COM (r =
.79, p < .0001), USC (r = .71, p < .0001), and ICS (r = .59, p = .005) all exhibited
significant and large effects. Pearson rs of the CSI and the pre-treatment SCORS
variables AFF (r = .50, p = .02) and SE (r = .48, p = .03) exhibited significant and
moderate effects. SCORS variable EIR (r = .42, p = .06) approached significance with a
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moderate effect. Associations between the pre-treatment SCORS subscales and total days
in the hospital (n = 21) further substantiate the convergent validity of the SCORS for use
with this uniquely disturbed cohort. Pearson r partial correlations for total days in
hospital and the pre-treatment SCORS variables COM (r = -.57, p = .009), USC (r = -.66,
p = .002), and ICS (r = -.68, p = .001) all exhibited significant and large effects in the
appropriate negative direction. Pearson r partial correlations for total days in hospital and
the pre-treatment SCORS variables AFF (r = -.38, p = .10) and EIR (r = -.39, p = .09)
approached significance with moderate effects in the appropriate negative direction.
Within-Group Analyses of Change
Paired-samples t tests illustrate pre- to post-treatment within-group change across
all six SCORS variables for both the Psychotherapy (Table 6) and Medication (Table 7)
groups. Patients in the Psychotherapy group exhibited significant change with robust
effects across all six object relations constructs (COM t[8] = 4.46, p = .002, d = 3.15;
AFF t[8] = 3.89, p = .005, d = 2.75; EIR t[8] = 2.39, p = .04, d = 2.39; USC t[8] = 6.53, p
= .0001, d = 4.62; SE t[8] = 4.53, p = .002, d = 3.20; and ICS t[8] = 5.01, p = .001, d =
3.54). Overall mean Cohen’s d effect size for the Psychotherapy group was large at 3.28.
Comparatively, patients of the Medication group did not fare as well relative to patients
receiving psychodynamic psychotherapy. Only two of six variables in the Medication
group reached statistical significance for pre- to post-treatment change (COM t[11] =
2.67, p = .02, d = 1.61 and EIR t[11] = 3.29, p = .007, d = 1.98). SCORS variables USC
t[11] = 2.04, p = .07, d = 1.23 and ICS t[11] = 1.74, p = .11, d = 1.05 approached
significance. Considering the small group size (and thus limited power), the results for
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the latter two variables may be indicative of a significant change. Liberally, these effect
sizes will be included in the Medication group’s mean effect size. The effect sizes of the
non-significant variables will be set to zero for this calculation. As such, overall mean
Cohen’s d effect size for the Medication group was .98.
Traditional Analyses of Between-Groups Change Using ‘Difference Scores’
Traditional analyses of between-groups change found that psychodynamic
psychotherapy for schizophrenia is superior to medication-only for treating schizophrenia
across multiple object relations domains (Table 8). Differences between treatments were
significant for three of six SCORS variables with large effects (COM t[19] = 2.27, p =
.04, d = 1.05; USC t[19] = 2.61, p = .02, d = 1.21; and SE t[19] = 2.40, p = .03, d =
1.13). SCORS variables AFF t[19] = 1.94, p = .07, d = .90 and ICS t[19] = 1.65, p = .12,
d = .77 both approached significance with a large and medium effect, respectively.
Considering the small sample size (and thus limited power) used in these analyses, the
results for the latter two variables may be indicative of significant between-groups
treatment effects. The SCORS variable EIR did not exhibit a statistically significant
between-groups effect (p = .86).
‘Recovered’ and/or ‘Positive Response’ to Treatment
Table 9 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS subscale Complexity of Representation (COM).
Utilizing Jacobson and Truax’ (1991) conservative estimates of recovery (i.e., RCI > 1.96
and SD > 2.0), 56% (5/9) of Psychotherapy patients met criteria for recovery in regard to
a multi-dispositional and differentiated view of self and others. An even more
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conservative estimate of recovery would be the 22% (2/9) of patients who achieved an
RCI > 1.96 and reached the pre-treatment mean of the patients represented in Peters et al.
(2006). In comparison, 42% (5/12) of the Medication patients met the conservative
estimate of recovery for COM. However, unlike the Psychotherapy group, no medicated
patients achieved the RCI > 1.96 score and pre-treatment mean of the patients represented
in Peters et al. (2006).
Table 10 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS subscale Affect Tone of Representations (AFF).
Conservative estimates of recovery found that 11% (1/9) of Psychotherapy patients met
criteria for improvement in their expectations of other as benevolent and helpful.
Interestingly, 33% (3/9) of the Psychotherapy patients achieved an RCI > 1.96 and
reached the pre-treatment mean of the patients in Peters et al. (2006), indicating that a
third of the Psychotherapy group ended treatment comparable to an average outpatient in
regard to affective expectations of others. No Medication patients met the Jacobson and
Truax’ (1991) conservative estimates of recovery or the RCI > 1.96 in combination with
the pre-treatment mean of the patients represented in Peters et al. (2006).
Table 11 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS subscale Emotional Investment in Relationships
(EIR). Conservative estimates of recovery found that 33% (3/9) of Psychotherapy
patients met criteria for improvement in regard to their desire to invest themselves
emotionally in interpersonal relationships. More conservatively, only 11% (1/9) of
psychotherapy patients achieved an RCI > 1.96 and reached the pre-treatment mean of
the patients in Peters et al. (2006). In comparison, 17% (2/12) of the Medication patients
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met the conservative estimate of recovery, and only 8% (1/12) of the medicated patients
achieved an RCI > 1.96 and reached the pre-treatment mean of the patients in Peters et al.
(2006).
Table 12 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS subscale Understanding of Social Causality (USC).
Conservative estimates of recovery found that 44% (4/9) of Psychotherapy patients met
the criteria for improvement in regard to their capacity to determine why people behave
the way they do in the interpersonal field. That is, nearly half of the Psychotherapy
patients by treatment’s end were significantly better equipped to read the motivation and
behavior of others, largely ameliorating one of the defining features of schizophrenic
suffering: the inability to realistically assess one’s social world. An even more
conservative estimate of recovery would be the 22% (2/9) of patients who achieved an
RCI > 1.96 and reached pre-treatment mean of the patients in Peters et al. (2006). In
comparison, 25% (3/12) of Medication patients met the conservative estimate of
recovery. Unlike the Psychotherapy group, no Medication patients achieved an RCI >
1.96 and reached pre-treatment mean of the patients in Peters et al. (2006).
Table 13 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS subscale Self-Esteem. Conservative estimates of
recovery found that 22% (2/9) of Psychotherapy patients met criteria for improvement in
their experience of self-esteem. Of note, 56% (5/9) of Psychotherapy patients achieved an
RCI > 1.96 and reached the pre-treatment mean of the patients in Peters et al. (2006).
That is, by treatment’s end, over half of the Psychotherapy patients had as much selfesteem as a mild to moderately severe clinical sample typical of an outpatient, university97

based psychotherapy clinic. In comparison, no medication patients met Jacobson and
Truax’ (1991) conservative estimates of recovery for Self-Esteem nor did any medicated
patients achieve an RCI > 1.96 and reach the pre-treatment mean of the patients in Peters
et al. (2006).
Table 14 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS subscale Identity and Coherence of the Self (ICS)
Conservative estimates of recovery found that 11% (1/9) of Psychotherapy patients met
criteria for improvement in their experience of themselves as moving forward in the
world with goals and a coherent, temporally stable sense of self. Of note, 67% (6/9) of
Psychotherapy patients achieved an RCI > 1.96 and reached the pre-treatment mean of
the patients in Peters et al. (2006). That is, by treatment’s end, two-thirds of the
Psychotherapy patients subjectively experienced themselves as an individual with a
personality as well integrated and as non-psychotic as patients seeking outpatient
psychotherapy. In comparison, no medication patients met Jacobson & Truax’ (1991)
conservative estimates of recovery while 25% (3/12) achieved an RCI > 1.96 and reached
the pre-treatment mean of the patients in Peters et al. (2006).
Table 15 reports improvement and deterioration rates of the Psychotherapy and
Medication patients for the SCORS composite variable (SCORS-C). Conservative
estimates of recovery found that 44% (4/9) of Psychotherapy patients met criteria for
improvement in their overall object relations. In comparison, only 8% (1/12) of
medication patients met Jacobson & Truax’ (1991) conservative estimates of recovery in
regard to overall object relations change.
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As can be viewed in Tables 9-15, for all six SCORS variables and SCORS-C,
rates of improvement rose for the Psychotherapy patients when the criteria were relaxed
according to Wise’s (2004) alternative ‘Positive Response’ criteria (RCI > 1.28 and SD >
1.0). Rates of ‘Positive Response’ to psychodynamic psychotherapy were as follows:
Complexity of Representations (7/9, 78%); Affect Tone of Representations (3/9, 33%);
Emotional Investment in Relationships (5/9, 56%); Understanding of Social Causality
(7/9, 78%); Self-Esteem (4/9, 44%); Identity and Coherence of the Self (6/9, 67%); and
SCORS-C (7/9, 78%).
In regard to the Medication group, as can be viewed in Tables 9-15, rates of
improvement generally - though not across the board - rose when the criteria were
relaxed according to Wise’s (2004) alternative ‘Positive Response’ criteria (RCI > 1.28
and SD > 1.0). Rates of ‘Positive Response’ to medication were as follows: Complexity
of Representations (5/12, 42%); Affect Tone of Representations (1/12, 8%); Emotional
Investment in Relationships (5/12, 42%); Understanding of Social Causality (6/12, 50%);
Self-Esteem (3/12, 25%); Identity and Coherence of the Self (4/12, 33%); and SCORS-C
(4/12, 33%).
Contrary to the PORTs negative expectations, it is important to note that whereas
no Psychotherapy patients exhibited clinically significant regression either at the
conservative or more relaxed criteria, there were in fact Medication patients who
exhibited clinically significant regression when inverting Wise’s (2004) ‘Positive
Response’ criteria (i.e., ‘Negative Response’). For Medication patients, 8% (1/12)
exhibited a ‘Negative Response’ for COM, AFF, EIR, ICS, SE, and SCORS-C. Similar to
conservative rates of improvement using Jacobson and Truax’ (1991) ‘Recovered’
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criteria, the Psychotherapy patients also fared better (percentage wise) on all variables
when using Wise’s (2004) ‘Positive Response’ criteria.
In regard to significance tests for SCORS-C, chi square analyses examining group
differences indicated results approaching significance with a large effect for number of
‘Recovered’ patients (χ2 = 3.70, p = .12, d = .93) as well as ‘Positive Response’ patients
(χ2 = 4.07, p = .08, d = .98). Considering the small sample size (and thus limited power)
of the present study, these results may be indicative of a significant and clinically
relevant difference between groups.
As mentioned, no patients receiving psychodynamic psychotherapy exhibited
clinically significant regression. In fact, any sign of regression indicated by a negative
RCI score was relatively rare for patients receiving psychodynamic psychotherapy. Out
of 63 computed RCI scores (i.e., nine patients multiplied by six SCORS variables and
SCORS-C) only 4 had a negative value (6%). In fact, for SCORS-C, not only were there
no psychotherapy patients with a negative RCI score, only one patient had a SCORS-C
RCI score below 1.00. This degree of consistent positive performance was not true of the
Medication group for which 25 of 84 RCI scores (30%) exhibited clinical regression.
Furthermore, 25% (4/12) of Medication patients had a negative RCI score for SCORS-C,
and, as mentioned, one Medication patient exhibited clinically significant regression for
the inversion of Wise’s ‘Positive Response’. A post hoc chi square analysis found that the
between-group difference in regard to presence of a negative treatment response as
indicated by a negative SCORS-C RCI was approaching significance with a large effect
(χ2 = 3.71, p = .10, d = .93). Considering the small sample size (and thus limited power)
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of the present study, these results may be indicative of a significant and clinically
relevant difference between groups.
Group Differences for RCI Scores
To maintain the optimal clinical utility of the present study, it was important to
also test for group differences on each of the six SCORS variables while controlling for
error measurement and regression to the mean. Providing data on these individual
variables offers practicing clinicians tangible, real-world information applicable to
clinical practice and therefore maintains the generalizability of the study. That is, it is
clinically useful to know if one treatment or the other specifically impacts a particular
dimension of object relations after controlling for artifacts. Table 16 reports the results of
independent-samples t tests conducted for all six SCORS variables to determine if the
Psychotherapy and Medication groups differed in regard to degree of change as measured
by the RCI. Again, because the RCI is reflective of real change and not the product of
measurement error it is a particularly useful indicator of clinical progress. Three of six
SCORS RCI values exhibited statistically significant and large differences between the
Psychotherapy and Medication groups. As can be seen by the RCI means in Table 16, all
results favored the Psychotherapy patients (COM, t[19] = 2.08, p = .05, d = .92; USC
t[19] = 2.44, p = .03, d = 1.08; and SE t[19] = 2.45, p = .02, d = 1.08). Two of six SCORS
RCI values approached statistical significance with large effects between the
Psychotherapy and Medication groups (AFF, t[19] = 2.01, p = .06, d = .89; ICS t[19] =
1.81, p = .09, d = .80). Again, considering the small sample size (and thus limited power)
of the present study, the results for the latter two variables may be indicative of a
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significant and clinically relevant difference between groups. The SCORS variable EIR
did not exhibit a statistically significant between-groups effect (p = .71). These results are
consistent with the traditional ‘difference score’ analyses presented in Table 8, though
after controlling for error measurement and regression to the mean, as can be seen by
comparison of effect sizes, results favoring the Psychotherapy group were even more
robust.
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IV. CONCLUSION
For far too long the empirical evidence supporting the positive effects of
psychodynamic psychotherapy for the treatment of schizophrenia has been neglected due
to a few core assumptions. As a result, there has been little space for its regular inclusion
in research; furthermore, its clinical application in standard treatment has been
diminishing for years.
First, the degenerative brain disease assumption has inculcated the idea in the
mental health profession that schizophrenia can only be managed rather than cured. As
extensively presented above, substantial evidence contradicts this notion on the grounds
that 1) the 19th century derived schizophrenia concept is grounded in often
unacknowledged non-epistemic ideas such as degeneration theory and philosophical
realism that serve to distort current conceptualization and treatment approaches; 2)
research investigating the effects of the duration of untreated schizophrenia has not
reliably shown a psychotoxic effect on the brain, nor has it been related to clinical
regression; and 3) ample longitudinal, cross-cultural data exist that document significant
improvement and recovery for people suffering with schizophrenia.
The second assumption is the supposed superiority and safety of medication
treatment for schizophrenia. Despite limited empirical backing, this assumption has been
reproduced continuously since the 1950s. In contrast, substantial evidence presented
earlier suggests that medications are of limited effectiveness, undeniably dangerous in
regard to an array of side-effects and may even preclude clinical progress/recovery.
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The third assumption, that is, the alleged ineffectiveness of psychodynamic
psychotherapy, has been directly stated in the schizophrenia Patient Outcome Research
Team study (PORT; Lehman & Steinwachs, 1998), a recent schizophrenia treatment
guideline published by biologically-based clinicians and researchers. PORTs
Recommendation 22 reads,
Individual and group psychotherapies adhering to a psychodynamic model
(defined as therapies that use interpretation of unconscious material and focus on
transference and regression) should not be used in the treatment of persons with
schizophrenia… there is a consensus that psychotherapy that promotes regression
and psychotic transference can be harmful to persons with schizophrenia (pp. 7-8;
my emphasis).
Since the PORT project was convened to review the clinical outcome literature to create
treatment guidelines for practicing psychiatrists and psychologists, this misperception is
extremely significant. Ver Eecke (2003), Gottdiener and Haslam (2003), and Silver
(2003) provide a clear, empirically- and theoretically-based critique of the mistaken
conclusions of the PORT. The results of the current investigation add weight to their
important criticism and directly challenge this flawed and widespread assumption.
Speaking directly to the empirical results of this dissertation project, there are four
major findings. First, the SCORS exhibits satisfactory inter-rater reliability for use with a
schizophrenic sample. Second, the SCORS, in a preliminary fashion, exhibits adequate
convergent and divergent validity for use with a schizophrenic sample. Third, contrary to
the PORTs admonishments that psychodynamic psychotherapy for the treatment of
schizophrenia is “harmful”, the results of this study indicate that psychodynamic
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psychotherapy is capable of providing reliable clinical change in the object relations of
schizophrenic patients. Fourth, in comparison to medication-only treatment,
psychodynamic psychotherapy results in significantly greater improvement in a variety of
object relations domains for patients suffering with schizophrenia.
Reliability estimates for the current investigation are consistent with past research
regarding the interrater reliability of the SCORS variables (e.g., Fowler et al., 2004).
Importantly, although the SCORS has been used to rate a diverse array of clinical and
non-clinical samples, as far as can be determined this is the first study to apply the
SCORS to a strictly schizophrenic sample. Thus, this study extends previous research
since the current findings indicate the SCORS can reliably measure TAT narratives
collected from severely psychotic individuals.
Correlational analyses helped illuminate preliminary divergent and convergent
validity of the SCORS for use with a psychotic sample. As expected, the affective
SCORS variables were unrelated to verbal functioning. This finding is important because
it is imperative that a narrative-based measure maintains its independence from verbal
acuity so that an individual’s capacity to verbalize him- or herself does not
disproportionately obscure accurate assessment of other constructs under investigation.
Further, support for the SCORS’ independence from verbal IQ is important due to the
fact that Karon and Vandenbos (1981) have already reported group differences for IQ in
their original study. Thus, the divergent validity observed in the present investigation
allows for analysis and reporting of non-redundant clinical outcome data. Divergent
validity was further supported since there were no significant correlations between the
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SCORS and age or education, as hypothesized. In sum, results provide preliminary
divergent validity evidence for use of the SCORS with a strictly psychotic sample.
As hypothesized, the SCORS’ cognitive variables (COM and USC) were related
to a commonly used measure of verbal IQ, suggesting that the SCORS can provide valid
measurement of cognitive processes such as verbal production. Also consistent with the
theoretical nature of the SCORS, correlational results with clinical status interviews (CSI)
and days spent in the hospital throughout the duration of the 20-month study exhibited
significant and moderate to large effect sizes. Determining SCORS object relations
variables capable of predicting inpatient stays may aid treatment planning by highlighting
particularly important areas of functioning worth focusing on to avoid hospitalizations.
The results of this study suggest that clinical attention to patients’ accurate appraisal of
social interactions (USC), degree of complex understanding of self and others (COM),
goal-directed behavior across time (ICS), affective expectations of others (AFF),
emotional investment in interpersonal relationships (EIR), as well as issues of self-esteem
are all potentially important areas of treatment focus that might prevent or decrease the
need for hospitalization.
Previous studies have found the SCORS to be a useful indicator of process
variables such as treatment continuation (Ackerman et al., 2000), suicidality (Kaslow et
al., 1997), childhood sexual abuse (Callahan, Price, & Hilsenroth, 2003; Slavin, Stein,
Pinsker, & Hilsenroth, 2007), social, vocational, and symptomatic functioning (Peters et
al., 2006), and mourning and loss (Field, Sturgeon, Puryear, Hibbard, & Horowitz, 2001),
all of which are highly relevant to the treatment of schizophrenia. Thus, the reliability and
validity results of this investigation represent a promising beginning for use of the
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SCORS in future process and outcome schizophrenia research. Inclusion of this widely
validated instrument capable of measuring personality processes beyond overt
symptomatic distress would also be a significant improvement over the majority of
schizophrenia outcome studies that overwhelmingly rely on self-report measures of
positive and negative symptoms, or, simply, medication compliance.
In regard to outcome, the current investigation replicates past results documenting
the effectiveness of psychodynamic psychotherapy for the treatment of schizophrenia
(see for a review Gottdiener & Haslam, 2002). However, this study is fairly unique in
contemporary research in that data for a completely non-medicated group is provided for
comparative purposes with a medication-only group. As a result, this study has been able
to test and, in the end, contest two important assumptions of the recent PORT study,
namely: 1) that psychodynamic psychotherapy of schizophrenia is “harmful”; and 2) that
medication treatments are preferable.
First, in regard to the psychotherapy of schizophrenia being “harmful”, the
present findings clearly indicate that psychotherapy was not harmful, but, to the contrary,
resulted in clinically reliable and valid change in both individual and group analyses
across all of the object relations constructs measured including a patients’ understanding
of the internal motivations, thoughts, and feelings of self and others (COM), emotional
investment in relationships (EIR), accurate appraisal of social interactions (USC), more
benevolent affective expectations of others (AFF), greater levels of self-esteem (SE),
more coherent sense of identity across time (ICS), and healthier global object relations
(SCORS-C). Far from being harmful, CS methodology assessing individual patients’
progress revealed that an impressive percentage of psychodynamic psychotherapy
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patients across all variables met ‘Positive Response’ (33-78%) and/or ‘Recovered’ (1156%) criteria. These results extend Karon & Vandenbos’ (1981) original findings that
found psychodynamic psychotherapy to be effective for treating the thought disorder
component of schizophrenia into the broader realm of interpersonal and self functioning
as measured by the SCORS. These within-group positive outcome results stand with or
without comparison to a medication-only group. This is a highly significant point
because a likely critique of the current design was the use of the older, typical
medications as opposed to the newer atypicals. However, as discussed above, such a
critique is empirically untenable due to the majority of clinical research that has found no
particular clinical advantages of the newer neuroleptic medications (e.g., the CATIE
study).
An additional empirical test of the PORT’s claim that psychodynamic
psychotherapy is harmful was carried out via a post hoc analysis of group differences
testing an indicator of clinical regression (i.e., negative RCI scores). In direct contrast to
the PORT’s claim, this analysis found that the number of Medication patients exhibiting a
negative RCI score on a measure of global object relations (SCORS-C) was significantly
greater than Psychotherapy patients. That is, regarding object relations change the
medication-only approach and not psychodynamic psychotherapy appeared to place
patients at greater risk for clinical regression and of course physiological side-effects for
which there are none for psychotherapy.
Unlike the psychotherapy patients, results for medication patients were
inconsistent as indicated by within-group and individual analyses. When assessed as a
group (Table 7), Medication patients failed to exhibit group change in regard to Affect
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Tone of Representations and Self-Esteem, two areas that were significantly and positively
impacted by psychodynamics psychotherapy. In regard to individual analyses using CS
methodology, while nearly every patient in the Psychotherapy group showed some degree
of positive improvement across all SCORS variables (i.e., as indicated by a positive RCI
score), this cannot be said of the Medication patients. This is to say, some Medication
patients did well on a few variables but not all, and, more problematically, some
Medication patients simply did poorly across the board. Empirically, this helps explain
statistically significant group differences for both ‘difference scores’ (Table 8) and RCI
scores (Table 16) favoring the psychodynamic psychotherapy patients for SCORS
variables COM, USC, SE, AFF, and ICS, in addition to the overall number of patients
exhibiting ‘Recovered’ and ‘Positive Response’ criteria for SCORS-C.
The less consistent outcome of the Medication patients suggests that while
medication treatment can be helpful for some patients, its generalized, non-specific
qualities might suggest a certain ‘hit or miss’ phenomenon. This seems to be the case in
this sample despite psychiatrists who made numerous medication adjustments based on
their expert, biological-based understanding of schizophrenia. In fact, because medication
treatments are of course not capable of handling the idiosyncratic thematic issues
troubling a patient, it would be unreasonable to expect medication to provide an
ameliorative effect for a patient’s interpersonal, self-esteem, and identity concerns among
a multitude of other complex issues gravely impacting a person suffering with
schizophrenia. However, in stark contrast and as many have theoretically suggested (e.g.,
Fromm-Reichmann, 1950), the capacity for a therapist to engage a patient as a complex
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person with unique difficulties and a life-story to share may be the driving curative factor
in psychotherapeutic work.
The erratic outcome and more significant regression observed for the Medication
patients are not particularly surprising. Writing in the New England Journal of Medicine
Goldstein (2003 notes, “One of the most striking features of modern medicines is how
often they fail to work. Even when they do work, they are often associated with serious
adverse reactions” (p. 553). The relatively high regression of the Medication patients
found in the present study is also consistent with the extraordinarily high early
discontinuation rates found in contemporary medication research (e.g., 74%) which
stands as another indicator of medication intolerability and ineffectiveness (Lieberman et
al., 2005). Of course, the empirically invalid assumption that safe and effective
alternatives such as psychodynamic psychotherapy do not exist limits treatment choices
and fosters the pessimistic submission that medication and their associated drawbacks
are, so to speak, ‘all that’s out there’. The results of this study, as well as other empirical
investigations of the effectiveness of psychodynamic psychotherapy strongly suggest
otherwise.
Investigating the results more closely, a few more important issues surface which
are highly relative to the comparative effectiveness of the interventions in question. To a
degree, and usually on a temporary basis, medication treatments have been shown to
minimize the positive symptoms of schizophrenia such as disorganized and delusional
thinking as well as hallucinations. Though, as presented above, such treatment successes
are often overestimated due to uncontrolled-for statistical confounds such as abrupt drug
withdrawal, clinically impractical exclusion criteria, multiple prescribing practices,
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excessive early discontinuation, and psychological and physiological impact of sideeffects (Karon, 1989; Jackson, 2005; Thornley & Adams, 1998). Nonetheless, despite
such confounds, decrease of positive symptoms via medication seems to be the one fairly
consistent and positive result of medication research and treatment. Indeed, in the present
study, most medication patients fared acceptably according to the SCORS cognitive
variables COM and USC. Nonetheless, the psychotherapy patients fared significantly
better for these variables. That is, psychotherapy outperformed medications in the very
area medications are expected to function most effectively. This is a key finding
considering that there is also considerable evidence that long- and short-term neuroleptic
use may actually harm cognitive functioning in a variety of domains (Kasper & Resinger,
2003; Minzenburg et al., 2004; Gilbertson & van Kammen, 1997; Mehta, Manes,
Magnolfi, Sahakian, & Robbins, 2004; Papageorgiou et al., 2003; Sweeney, Keilp, Haas,
Hill, & Weiden, 1991; Vitiello et al., 1997; Cassens, Inglis, Appelbaum, & Gutheil, 1990;
King, 1994; Ridout & Hindmarch, 2003; Brebion, Amador, Smith, & Gorman, 1998;
Cleghorn, Kaplan, Szechtman, Szechtman, & Brown, 1990; Rammsayer, 1997; McCartan
et al., 2001; Scherer et al., 2004), thus making viable non-biological alternatives an
imperative.
Unlike the partial success of medications for improving the positive symptoms
associated with schizophrenia, it is well documented that neuroleptic use – typical or
atypical – does little to ameliorate the debilitating negative symptoms associated with
schizophrenia (Jackson, 2005). This study builds upon this widely accepted empirical fact
and provides additional evidence that it might be unrealistic to expect medication
treatment to positively impact object relations domains such as self-esteem, affective
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expectation of others, and identity and coherence of self, all of which are dramatically
impacted by negative symptoms such as social withdrawal, depressive collapse,
anhedonia, alogia, and avolition. Indeed, in these object relations domains
psychodynamic psychotherapy outperformed the medication group on all accounts.
Considering convergent validity results suggesting that such factors may also be potential
predictors of hospitalization, the role of psychodynamic psychotherapy for schizophrenia
may not only be clinically valuable in regard to mental health and overall quality of life,
but economically beneficial as well (Warner, 2004).
It should be recalled that there were a number of factors working against the
psychotherapy patients that may render the positive and comparably superior results of
this type of treatment an underestimation of the potential effectiveness of psychodynamic
psychotherapy. These factors include inexperienced therapist trainees, Caucasian
therapists treating and attempting to relate/engage generally inner-city African-American
patients during the time of the Detroit race riots in the 1960s, fairly chronic rather than
early episode patients and, on average, only one session per week as opposed to the 2-3
times per week recommended by most clinicians experienced in the psychotherapy of
schizophrenia (e.g. Sullivan, 1962). Therefore, even under these difficult circumstances
psychodynamic interventions appear quite capable of providing substantial clinical
benefit over and above the effects of medication-only treatment.
Due to the growing evidence of the danger and ineffectiveness of neuroleptic
treatment for schizophrenia, many psychologists, and perhaps even more importantly,
psychiatrists and the news media are beginning to question the degenerative as well as the
‘medicate continuously and as early as possible’ assumptions. In a 2006 New York Times
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(NYT) interview, Dr. William Carpenter, director of the University of Maryland’s
Psychiatric Research Center and editor of the journal Schizophrenia Bulletin reports, “My
personal view is that the pendulum has swung too far, and there’s a knee-jerk reaction out
there that says that any period off medication, even for research, is on the face of it
unethical” (my emphasis). Oddly, in this same NYT interview, despite his own coauthored meta-analysis that found no association between untreated schizophrenia with
neurocognitive deficits, morphological changes in the brain, or symptom relapse (i.e.,
Perkins et al., 2005), Dr. Jeffrey Lieberman responds,
I am usually a pretty moderate person. But on this I am 110 percent emphatic: If
the diagnosis is clear, not treating with medication is a huge mistake that risks the
person’s best chance at recovery. It’s just flat out nuts.
Beyond his own meta-analytic findings refuting his comments, there are many
longitudinal and psychotherapy outcome studies indicating that not medicating can be
equally and even more helpful than medication treatments. In fact, as shown above,
reviews of the schizophrenia outcome literature suggest that exposure to neuroleptic
medications may negatively impact treatment outcome and even preclude recovery.
It is clear that due to the complexity inherent in any treatment of schizophrenia
a psychiatry-psychology alliance might be greatly welcomed by frontline care providers
who are often frustrated and dismayed by the limited effectiveness and all-too-prevalent
side-effects of medication treatments (Breggin, 1991; Jackson, 2005; Whitaker, 1992). It
has been the explicit intention of the current theoretical and empirical investigation to
open a space within which biopsychiatry and psychology can work together, each
providing the unique tools and insights of their distinct professions.
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Mirroring the main premise of this dissertation project, Bola (2006) implored researchers
to consider that psychotherapy outcome research – with and without adjunctive
medications – should not be prohibited based on the assumptions deconstructed
throughout this dissertation project. He writes,
In the absence of substantive evidence of long-term harm from short periods of
medication-free research in schizophrenia, a categorical prohibition of
medication-free research in early episode schizophrenia on the ethical grounds of
harm to human subjects should probably be reconsidered (p. 294).
Methodological designs for this type of inclusive, non-biased research have been
provided by Emanuel and Miller (2001), Alanen, (1997), Seikkula et al. (2003) and
Deikman and Whitaker (1979) among others to help clinicians and researchers
satisfactorily test the effectiveness of drug and non-drug treatments whether independent
of each other or combined. Indeed, the time is ripe for researchers and clinicians to
respond positively to the call for fresh approaches and insights into schizophrenic
suffering minus the suffocating biases that have held the field back for over half a
century.
There are a few significant limitations of the present study. First, although the
sample size was intentionally limited by the original investigators to control for quality of
psychotherapy provided to patients, its restricted power necessitates a degree of caution
when interpreting the results. Future studies might consider using external raters to assess
treatment fidelity and quality rather than relying on restricted n-size. Such covariates
would not only allow for increased sample size, but would also provide potentially
interesting clinical information. Second, patients in this sample were generally urban
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minorities of a low SES. Studies with a more diverse sample might provide useful
information pertaining to the effects of these demographic variables. Third, future studies
should include a mixed treatment group to investigate the effectiveness of combined
treatments. Due to lost data, the mixed group originally included in Karon and
Vandenbos (1981) could not be assessed for object relations change. Fourth, the
Medication patients in this study received older, typical neuroleptics. At first glance, this
might be deemed a fatal flaw of this study. However, as the CATIE study and other
recent investigations reported above clearly suggest, the differences between the older
and newer neurolpetics have been greatly overstated. This is true of clinical improvement
as well as of troubling side-effects. Most importantly, many of these limitations will only
be amenable to change if studies such as this one are received with openness and a level
of scientific inquiry greatly needed if the schizophrenia research and clinical community
is to accurately assess the quality of its different treatment approaches.
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Table 1. Most Commonly Prescribed Neuroleptic Medications for the Treatment of Schizophrenia

Generic Name

Brand Name

Typical Neuroleptics

chlorpromazine
fluphenazine
haloperidol
thiothixene
trifluoperazine
perphenazine
thioridazine

Thorazine
Prolixin
Haldol
Navane
Stelazine
Trilafon
Mellaril

Atypical Neuroleptics

aripiprazole
risperidone
clozapine
olanzapine
ziprasidone

Abilify
Risperdal
Clozaril
Seroquel
Geodon
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Table 2. Example of Non-Equivalent Dosing

Olanzapine
(atypical neuroleptic)
Low Dose
Medium Dose
High Dose

5mg +/- 2.5 mg
10 mg +/- 2.5 mg
15 mg +/- 2.5 mg
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Haloperidol
(typical neuroleptic)
10-20 mg
10-20 mg
10-20 mg

Table 3. Interrater Reliability of the SCORS Variables

SCORS Variable
COMb

ICC (1,1)aj
.71

AFFc
EIRd

.71
.75

EIMe
USCf
AGGg

.71
.74
.83

She
ICSi

.76
.77

Note. n = 20. aICC = intraclass correlation coefficients (1,1); (Shrout & Fleiss, 1979) oneway random effects model; bCOM = Complexity of Representations; cAFF = Affect Tone
of Representations; dEIR = Emotional Investment in Relationships; eEIM = Emotional
Investment in Values and Morality; fUSC = Understanding of Social Causality; gAGG =
Experience and Management of Aggressive Impulses; hSE = Self-Esteem; iICS = Identity
and Coherence of the Self. jICC < .40 = poor; .40 - .59 = fair; .60 - .74 = good; ≥ .75 =
excellent.
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Table 4. SCORS Means of Outpatients Experiencing Mild to Moderate Distress as Reported in
Peters et al. (2006)

SCORS Variable
COMa

Mean
4.02

SD
.96

AFFb
EIRc

3.29
3.56

1.02
.94

USCd
SEe
ICSf

3.94
3.12
3.74

.98
.81
.94

Note. n = 90. aCOM = Complexity of Representations; bAFF = Affect Tone of
Representations; cEIR = Emotional Investment in Relationships; dUSC = Understanding
of Social Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self.
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Table 5. Convergent and Divergent Validity of the SCORS with a Schizophrenic Sample

COMf

AFFg

EIRh
r
p

rl

p

Hospitala

-.57

.009

Verbal IQb
Agec
Educationd
CSIe

.52 .03
-.04 .90 .08
.15 .53
-.15 .51 -.07
.39 .15
-.01 .97 -.08
.79 <.0001 .50 .02 .42

r

p

-.38 .10 -.39

USCi
r

.09 -.66
.76
.78
.79
.06

SEj
p

.002

r

ICSk
p

r

p

-.40 .08 -.68 .001

.45 .01
.16 .54
.02 .92
-.04 .86
.41 .13
.12 .66
.71 <.0001 .48 .03

.37
.11
.35
.59

.15
.62
.20
.005

Note. aHospital = Total days in hospital through 20-months (n = 21); bVerbal IQ as
measured by WAIS (Weschler, 1955; n = 17); cAge (n = 21); dEducation (n = 15); eCSI =
Clinical Status Interview assessing global health-sickness and psychiatric
symptomatology (n = 21); fCOM = Complexity of Representations; gAFF = Affect Tone
of Representations; hEIR = Emotional Investment in Relationships; iUSC =
Understanding of Social Causality; jSE = Self-Esteem; kICS = Identity and Coherence of
the Self; lPearson r correlational coefficients are considered to represent a small effect
from .1 to .3, a medium effect from .3 to .5, and a large effect if greater than .5 (Cohen,
1988).
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Table 6. Means, Standard Deviations, and Paired-Samples T Tests for Psychotherapy Group

COMa
AFFb
EIRc
USCd
SE e
ICSf

Psychotherapy (n = 9)
Pre-Treatment
Post-Treatment
M
SD
M
SD
1.64
.36
3.20
1.06
2.82
.54
3.59
.63
2.21
.36
2.79
.78
1.69
.36
3.16
.92
2.76
.47
3.72
.53
2.86
.57
4.11
.55

df
8
8
8
8
8
8

t
4.46
3.89
2.39
6.53
4.53
5.01

p
.002
.005
.04
.0001
.002
.001

ES dgh
3.15
2.75
2.39
4.62
3.20
3.54

Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations;
c
EIR = Emotional Investment in Relationships; dUSC = Understanding of Social
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect
from .2 to .5, a medium effect from .5 to .8, and a large effect if greater than .8.
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Table 7. Means, Standard Deviations, and Paired-Samples T Tests for Medication Group

COM
AFFb
EIRc
USCd
SE e
ICSf

a

Medication (n = 12)
Pre-Treatment
Post-Treatment
M
SD
M
SD
2.02
.64
2.65
.79
2.85
.72
3.08
.73
1.98
.57
2.52
.68
2.00
.68
2.53
.85
3.27
.55
3.07
.64
3.03
.98
3.58
.70

df
11
11
11
11
11
11

t
2.67
1.25
3.29
2.04
0.91
1.74

p
.02
.24
.007
.07
.38
.11

ES dgh
1.61
0.75
1.98
1.23
0.55
1.05

Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations;
c
EIR = Emotional Investment in Relationships; dUSC = Understanding of Social
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect
from .2 to .5, a medium effect from .5 to .8, and a large effect if greater than .8.
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Table 8. Traditional Analyses of Between-Groups Change Using ‘Difference Scores’

Psychotherapy (n = 9)
M

SD

Medication (n = 12)
M

SD

df

t

p

ES dgh

COMa

1.56

1.05

0.63

0.82

19

2.27

.04

1.05

AFFb

0.77

0.59

0.23

0.65

19

1.94

.07

0.90

EIRc

0.58

0.73

0.53

0.56

19

0.18

.86

0.08

USCd

1.47

0.68

0.53

0.90

19

2.61

.02

1.21

SEe

0.97

.64

0.20

0.77

19

2.40

.03

1.13

ICSf

1.25

0.75

0.55

1.09

19

1.65

.12

0.77

Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations;
c
EIR = Emotional Investment in Relationships; dUSC = Understanding of Social
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect
from .2 to .5, a medium effect from .5 to .8, and a large effect if greater than .8.
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Table 9. Number of Individual Psychotherapy and Medication Patients Meeting Clinical Significance
Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS Complexity of
Representations (COM)

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
7
0
0
5
0 (0%)
5 (56%)

Medication (n = 12)
Improved
Deteriorated
5
0
6
0
5 (42%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

7
7
7 (78%)

0
0
0 (0%)

6
7
5 (42%)

1
0
0 (0%)

RCI > 1.96 and
Peters et al. (2006)

2 (22%)

n/a

0 (0%)

n/a

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 10. Number of Individual Psychotherapy and Medication Patients Meeting Clinical
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS Affect
Tone of Representations (AFF)

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
3
0
1
0
1 (11%)
0 (0%)

Medication (n = 12)
Improved
Deteriorated
1
0
1
0
0 (0%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

5
4
3 (33%)

0
0
0 (0%)

1
2
1 (8%)

1
1
1 (8%)

RCI > 1.96 and
Peters et al. (2006)

3 (33%)

n/a

0 (0%)

n/a

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 11. Number of Individual Psychotherapy and Medication Patients Meeting Clinical
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS
Emotional Investment in Relationships (EIR)

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
4
0
3
0
3 (33%)
0 (0%)

Medication (n = 12)
Improved
Deteriorated
4
0
2
0
2 (17%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

6
5
5 (56%)

1
0
0 (0%)

6
6
5 (42%)

1
1
1 (8%)

RCI > 1.96 and
Peters et al. (2006)

1 (11%)

n/a

1 (8%)

n/a

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 12. Number of Individual Psychotherapy and Medication Patients Meeting Clinical
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS
Understanding of Social Causality (USC)

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
7
0
4
0
4 (44%)
0 (0%)

Medication (n = 12)
Improved
Deteriorated
4
0
4
0
3 (25%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

8
7
7 (78%)

0
0
0 (0%)

6
6
6 (50%)

0
0
0 (0%)

RCI > 1.96 and
Peters et al. (2006)

2 (22%)

n/a

0 (0%)

n/a

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 13. Number of Individual Psychotherapy and Medication Patients Meeting Clinical
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS SelfEsteem (SE)

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
6
0
2
0
2 (22%)
0 (0%)

Medication (n = 12)
Improved
Deteriorated
2
1
0
0
0 (0%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

7
4
4 (44%)

0
0
0 (0%)

4
5
3 (25%)

1
1
1 (8%)

RCI > 1.96 and
Peters et al. (2006)

5 (56%)

n/a

0 (0%)

n/a

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 14. Number of Individual Psychotherapy and Medication Patients Meeting Clinical
Significance Criteria for ‘Recovered’, ‘Positive Response’, and Peters et al. (2006) for SCORS
Identity and Coherence of the Self (ICS)

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
6
0
1
0
1 (11%)
0 (0%)

Medication (n = 12)
Improved
Deteriorated
3
1
0
0
0 (0%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

7
6
6 (67%)

0
0
0 (0%)

6
6
4 (33%)

1
1
1 (8%)

RCI > 1.96 and
Peters et al. (2006)

6 (67%)

n/a

3 (25%)

n/a

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 15. Number of Individual Psychotherapy and Medication Patients Meeting Clinical
Significance Criteria for ‘Recovered’ and ‘Positive Response’ for SCORS-C

Criterion
RCI > 1.96
SD > 2.0
‘Recovered’a

Psychotherapy (n = 9)
Improved
Deteriorated
6
0
4
0
4 (44%)
0 (0%)

Medication (n = 12)
Improved
Deteriorated
4
0
3
0
1 (8%)
0 (0%)

RCI > 1.28
SD > 1.0
‘Positive’b

7
7
7 (78%)

5
5
4 (33%)

0
0
0 (0%)

1
1
1 (8%)

Note. a‘Recovered’: RCI > 1.96, SD > 2.0; b‘Positive Response’: RCI > 1.28, SD > 1.0.
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Table 16. Differences in RCI between Psychotherapy and Medication Treatments

Psychotherapy (n = 9)
M

SD

Medication (n = 12)
M

SD

df

t

p

ES dgh

COMa

3.50

2.44

1.59

1.78

19

2.08

.05

0.92

AFFb

1.59

1.14

0.55

1.20

19

2.01

.06

0.89

EIRc

1.78

2.10

1.47

1.56

19

0.38

.71

0.18

USCd

3.47

1.79

1.38

2.05

19

2.44

.03

1.08

SEe

2.30

1.45

0.59

1.68

19

2.45

.02

1.08

ICSf

2.21

1.20

1.02

1.67

19

1.81

.09

0.80

Note. aCOM = Complexity of Representations; bAFF = Affect Tone of Representations;
c
EIR = Emotional Investment in Relationships; dUSC = Understanding of Social
Causality; eSE = Self-Esteem; fICS = Identity and Coherence of the Self; g ES = effect
size Cohen’s (1977) d; hCohen’s d effect sizes are considered to represent a small effect
from .2 to .5, a medium effect from .5 to .8, and a large effect if greater than .8.
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